EP3430012B1 - Dérivés de 4,6-dihydropyrrolo[3,4-c]pyrazole-5(1h)-carbonitrile pour le traitement du cancer - Google Patents

Dérivés de 4,6-dihydropyrrolo[3,4-c]pyrazole-5(1h)-carbonitrile pour le traitement du cancer Download PDF

Info

Publication number
EP3430012B1
EP3430012B1 EP17713402.0A EP17713402A EP3430012B1 EP 3430012 B1 EP3430012 B1 EP 3430012B1 EP 17713402 A EP17713402 A EP 17713402A EP 3430012 B1 EP3430012 B1 EP 3430012B1
Authority
EP
European Patent Office
Prior art keywords
dihydropyrrolo
pyrazole
carbonitrile
phenyl
cyano
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP17713402.0A
Other languages
German (de)
English (en)
Other versions
EP3430012A1 (fr
Inventor
Alison Jones
Mark Ian Kemp
Martin Lee Stockley
Michael D. WOODROW
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mission Therapeutics Ltd
Original Assignee
Mission Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mission Therapeutics Ltd filed Critical Mission Therapeutics Ltd
Publication of EP3430012A1 publication Critical patent/EP3430012A1/fr
Application granted granted Critical
Publication of EP3430012B1 publication Critical patent/EP3430012B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Definitions

  • the present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs) and/ or desumoylating enzymes.
  • the invention relates to the inhibition of ubiquitin C-terminal hydrolase 7 or ubiquitin specific peptidase 7 (USP7).
  • the invention further relates to the use of DUB or desumoylating inhibitors in the treatment of cancer.
  • Ubiquitin is a small protein consisting of 76 amino acids that is important for the regulation of protein function in the cell.
  • ubiquitin there are a growing number of structurally related ubiquitin-like molecules (UBLs) that modify substrates in parallel but distinct cellular pathways.
  • proteins include but are not restricted to small ubiquitin-like modifier (SUMO), interferon-stimulated gene 15 (ISG15), ubiquitin-related modifier-1 (URM1), neuronal-precursor-cell-expressed developmentally downregulated protein-8 (NEDD8), human leukocyte antigen F-associated (FAT10), autophagy-8 (ATG8) and -12 (ATG12), few ubiquitin-like protein (FUB1), membrane-anchored UBL (MUB), ubiquitin fold-modifier-1 (UFM1) and ubiquitin-like protein-5 (UBL5).
  • SUMO small ubiquitin-like modifier
  • ISG15 interferon-stimulated gene 15
  • UDM1 ubiquitin-related modifier-1
  • NEDD8 neuronal-precursor-cell-expressed developmentally downregulated protein-8
  • FATG8 human leukocyte antigen F-associated
  • AGT8 autophagy-8
  • AGT8 autophagy-8
  • UG12 ubiquitin
  • Ubiquitylation and deubiquitylation of ubiquitin and UBLs are enzymatically mediated processes by which ubiquitin or UBLs are covalently bound or cleaved from a target protein by ubiquitylating enzymes and deubiquitylating enzymes (DUBs).
  • DUBs ubiquitylating enzymes and deubiquitylating enzymes
  • SENPs Sentrin specific proteases
  • the ubiquitylation and deubiquitylation processes have been implicated in the regulation of many cellular functions including cell cycle progression, apoptosis, modification of cell surface receptors, regulation of DNA transcription and DNA repair.
  • the ubiquitin system has been implicated in the pathogenesis of numerous disease states including inflammation, viral infection, metabolic dysfunction, CNS disorders, and oncogenesis.
  • USP7 is a DUB with strong oncology links and is an established anti-cancer target.
  • USP7 The rationale behind targeting USP7 is principally due to its well validated role in regulating multiple oncogenes, tumour suppressors, viral proteins and epigenetic regulators including Phosphatase and tensin homolog (PTEN), Forkhead box protein O4 (FOXO4), the p53:HDM2 axis and DNA (cytosine-5)-methyltransferase 1 (DNMT1).
  • PTEN Phosphatase and tensin homolog
  • FOXO4 Forkhead box protein O4
  • DNMT1 DNA
  • Inhibition of USP7 causes degradation of Human double minute 2 homolog (HDM2), stabilisation of p53 and activation of apoptosis in tumour cells meaning it is a potential target for cancers where there is deregulated HDM2 expression ( ⁇ 7% of all cancers) and/or wild-type p53 ( ⁇ 50% of all cancers).
  • USP7 inhibition has also been shown to reduce the immune-suppressive capacity of regulatory T
  • the ubiquitin-proteasome system has gained interest as a target for the treatment of cancer following the approval of the proteasome inhibitor bortezomib for the treatment of multiple myeloma. Extended treatment with bortezomib is limited by its associated toxicity and drug resistance. However, therapeutic strategies that target specific aspects of the ubiquitin-proteasome pathway upstream of the proteaseome, such as DUBs, are predicted to be better tolerated. Although there is strong interest in this field, DUB inhibitors have yet to enter the market ( Kemp M, Progress in Medicinal Chemistry 2016; 55:140-192 ). Thus, there is a need for compounds and pharmaceutical compositions to inhibit DUBs such as USP7 for the treatment of indications where DUB activity is observed, including, although not limited to, cancer.
  • WO2013044865 describes the compounds benzyl (4-(5-cyano-5,6-dihydropyrrolo[3,4- d ][1,2,3]triazol-2(4 H )-yl)-3-fluorophenyl)carbamate and 2-(2-fluoro-4-nitrophenyl)-2,6-dihydropyrrolo[3,4- c ]pyrazole-5(4 H )-carbonitrile as intermediates in methods for preparing antibiotic compounds.
  • the invention relates to compounds of formula I as described hereinafter.
  • the invention also relates to pharmaceutical compositions comprising the compounds of the present invention and one or more pharmaceutically acceptable excipients.
  • the compounds of the invention are useful for the treatment of cancer.
  • any group of the compounds of formula I have been referred to as optionally substituted, this group may be substituted or unsubstituted. Substitution may be by one or more of the specified substituents which may be the same or different. It will be appreciated that the number and nature of substituents will be selected to avoid any sterically undesirable combinations.
  • an alkyl, alkylene, alkoxy, alkenyl, or alkynyl substituent (or linker) group or an alkyl, alkenyl moiety in a substituent group may be linear or branched.
  • C x -C y alkyl refers to a saturated aliphatic hydrocarbon group having x-y carbon atoms which may be linear or branched.
  • C 1- C 6 alkyl contains from 1 to 6 carbon atoms and includes C 1 , C 2 , C 3 , C 4 , C 5 and C 6 .
  • "Branched" means that at least one carbon branch point is present in the group. For example, tert-butyl and isopropyl are both branched groups.
  • C 1- C 6 alkyl groups include methyl, ethyl, propyl, 2-methyl-1-propyl, 2-methyl-2-propyl, 2-methyl-1-butyl, 3-methyl-1-butyl, 2-methyl-3-butyl, 2,2-dimethyl-1-propyl, 2-methyl-pentyl, 3-methyl-1-pentyl, 4-methyl-1-pentyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 2,2-dimethyl-1-butyl, 3,3-dimethyl-1-butyl, 2-ethyl-1-butyl, n-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl and n-hexyl.
  • substituted C 1 -C 6 alkyl include CF 3 , CH 2 CF 3 , CH 2 CN, CH 2 OH and CH 2 CH 2 OH
  • a C x -C y alkylene group or moiety may be linear or branched and refers to a divalent hydrocarbon group having one less hydrogen atom from C x- C y alkyl as defined above.
  • Examples of C 1- C 6 alkylene groups include methylene, ethylene, n-propylene, n-butylene, methylmethylene and dimethylmethylene.
  • C 2 -C 6 alkenyl refers to a linear or branched hydrocarbon chain radical containing at least two carbon atoms and at least one double bond and includes C 2 -C 4 alkenyl.
  • alkenyl groups include ethenyl, propenyl, 2-propenyl, 1-butenyl, 2-butenyl, 1-hexenyl, 2-methyl-1-propenyl, 1,2-butadienyl, 1,3-pentadienyl, 1,4-pentadienyl and 1-hexadienyl.
  • C 2 -C 6 alkenylene refers to linear or branched hydrocarbon group having one less hydrogen atom from C 2 -C 6 alkenyl as defined above.
  • Examples of C 2 -C 6 alkenylene include ethenylene, propenylene and butenylene.
  • C 2 -C 6 alkynyl refers to a linear or branched hydrocarbon chain radical containing at least two carbon atoms and at least one triple bond.
  • alkenyl groups include ethynyl, propynyl, 2-propynyl, 1-butynyl, 2-butynyl and 1-hexynyl.
  • C 1 -C 6 alkoxy refers to a group or part of a group having an -O-C x -C y alkyl group according to the definition of C x- C y alkyl above.
  • C 1- C 6 alkoxy contains from 1 to 6 carbon atoms and includes C 1 , C 2 , C 3 , C 4 , C 5 and C 6 .
  • Examples of C 1- C 6 alkoxy include methoxy, ethoxy, propoxy, isopropoxy, butoxy, pentoxy and hexoxy.
  • Examples of substituted C 1 -C 6 alkoxy include OCF 3 , OCHF 2 , OCH 2 CF 3 , CH 2 CH 2 OCH 3 and CH 2 CH 2 OCH 2 CH 3 .
  • halogen refers to chlorine, bromine, fluorine or iodine atoms, in particular chlorine or fluorine atoms.
  • the cycloalkyl, heterocyclyl, aryl and heteroaryl rings disclosed herein and within the definitions of R 1a , R 1b , R 1c , R 1d , R 13 , R 16 , R 12 , B and D do not include any unstable ring structures or, in the case of heteroaryl and heterocyclic ring systems, any O-O, O-S or S-S bonds.
  • the ring systems may be monocyclic or bicyclic. Bicyclic ring systems include bridged, fused and spiro ring systems.
  • a substituent if present may be attached to any suitable ring atom which may be a carbon atom or, in the case of heteroaryl and heterocyclic ring systems, a heteroatom.
  • cycloalkyl refers to a monocyclic saturated or partially unsaturated, non-aromatic ring, wherein all of the ring atoms are carbon, and having the number of ring atoms as indicated.
  • C 3 -C 10 cycloalkyl refers to a monocyclic or bicyclic hydrocarbon ring containing 3 to 10 carbon atoms.
  • C 3 -C 10 cycloalkyl examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl and decahydronaphthalenyl.
  • Bicyclic cycloalkyl groups include bridged ring systems such as bicycloheptane and bicyclooctane.
  • aryl group / moiety refers to any monocyclic or bicyclic hydrocarbon group comprising at least one aromatic group and having from 5 to 10 carbon atom ring members.
  • aryl groups include phenyl and naphthyl.
  • Bicyclic rings may be fused aromatic rings where both rings are aromatic, for example, naphthalenyl.
  • Preferred aryl groups are phenyl and naphthyl, more preferably phenyl.
  • Heteroaryl as used herein means a polyunsaturated, monocyclic or bicyclic 5 to 10 membered aromatic moiety containing at least one and up to 5 heteroatoms, particularly 1, 2 or 3 heteroatoms selected from N, O and S, and the remaining ring atoms are carbon atoms, in stable combinations known to the skilled person. Heteroaryl ring nitrogen and sulphur atoms are optionally oxidised, and the nitrogen atom(s) are optionally quaternized.
  • a heteroaryl ring can be a single aromatic ring or a fused bicyclic ring where the bicyclic ring system can be aromatic, or one of the fused rings is aromatic and the other is at least partially saturated.
  • a bicyclic heteroaryl is one in which the entire fused ring system is aromatic.
  • a bicyclic heteroaryl can have the at least one heteroatom in either of the fused rings.
  • a bicyclic ring with an aromatic ring fused to a partially saturated ring may contain the at least one heteroatom in the aromatic ring or the partially saturated ring.
  • Attachment of the bicyclic ring to the group it is a substituent of may be via either a heteroatom containing ring or a carbon only containing ring.
  • the point of attachment of heteroaryl to the group it is a substituent of can be via a carbon atom or a heteroatom (e.g. nitrogen).
  • heteroaryl rings include pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, furyl, pyrrolyl, oxazolyl, thiazolyl, pyrazolyl, triazolyl, tetrazolyl, indolyl, indolizinyl, isoindolyl, purinyl, furazanyl, imidazolyl, indazolyl, isothiazolyl, isoxazolyl, oxadiazolyl, tetrazolyl, thiadiazolyl, benzofuranyl, isobenzofuranyl, benzothiophenyl, isobenzothiophenyl, benzimidazolyl, benzothiazolyl, napthyridinyl, pteridinyl, pyrazinyl, quinolinyl, isoquinolinyl, cinnolinyl, phthalazin
  • Heterocyclyl or “heterocyclic” as used herein in describing a ring means, unless otherwise stated, a monocyclic saturated or partially unsaturated, non-aromatic ring or a bicyclic saturated or partially unsaturated ring, wherein the bicyclic ring system is non-aromatic, the mono- or bicyclic ring having, for example, 3 to 10 members, where at least one member and up to 5 members, particularly 1, 2 or 3 members of the ring are heteroatoms selected from N, O and S, and the remaining ring atoms are carbon atoms, in stable combinations known to those of skill in the art.
  • Heterocyclic ring nitrogen and sulphur atoms are optionally oxidised, and the nitrogen atoms(s) are optionally quaternized.
  • the heterocyclic ring may be a fused ring to another ring system to form a bicycle, i.e. one or two of the heterocyclic ring carbons is common to an additional ring system.
  • the second ring can be aromatic, e.g. a fused phenyl, pyridyl, pyrazolyl, or the like.
  • heterocyclyl may be linked through carbon or a heteroatom to the remainder of the molecule and in instances where the heterocylyl is a bicyclic ring, the link may be via the heteroatom containing ring or the fused ring.
  • heterocyclyl groups include azetidinyl, pyrrolidinyl, piperidinyl, azepanyl, diazepanyl, dihydrofuranyl (e.g.
  • substituted heterocyclyl rings include for example 4,5-dihydro-1H-maleimido, tetramethylenesulfoxide and hydantoinyl.
  • Optionally substituted as applied to any group means that the said group may if desired be substituted with one or more substituents (e.g., 1, 2, 3 or 4 substituents) which may be the same or different.
  • substituents e.g., 1, 2, 3 or 4 substituents
  • C 1 -C 6 alkyl including C 1 -C 4 alkyl, C 1 -C 3 alkyl and C 1 -C 2 alkyl
  • C 1 -C 6 alkoxy including C 1 -C 4 alkoxy, C 1 -C 3 alkoxy and C 1 -C 2 alkoxy
  • C 2 -C 6 alkenyl including C 2 -C 4 alkenyl
  • C 2 -C 6 alkynyl including C 2 -C 4 alkynyl
  • C 1 -C 6 alkylene including C 1 -C 3 alkylene
  • C 2 -C 6 alkenylene include halogen, cyano, oxo, nitro, amino, amido, hydroxy, C 1 -C 6 alkyl or C 1 -C 3 alkyl, C 1 -C 6 alkoxy or C 1 -C 3 alkoxy, aryl
  • suitable substituents may be selected from halogen, hydroxyl, thiol, cyano, amino, amido, nitro and SF 5 (a known mimetic of nitro), in particular, halogen (preferably fluorine or chlorine), hydroxyl and cyano.
  • substituents for all remaining "substituted” and “optionally substituted” moieties include halogen, cyano, oxo, nitro, amino, amido, hydroxy, amido, C 1 -C 6 alkyl or C 1 -C 3 alkyl, C 1 -C 6 alkoxy or C 1 -C 3 alkoxy, aryl, heteroaryl, heterocyclyl, C 3 -C 6 cycloalkyl, C 1-3 alkylamino, C 2-6 alkenylamino, di-C 1 -C 3 alkylamino, C 1 -C 3 acylamino, di-C 1 -C 3 acylamino, carboxy, C 1 -C 3 alkoxycarbonyl, carboxamidyl, carbamoyl, mono-C 1-3 carbamoyl, di-C 1-3 carbamoyl or any of
  • substituents for "substituted” and “optionally substituted” rings include in particular, fluorine, chlorine, oxo, cyano, C 1 -C 3 alkyl, C 1 -C 3 alkoxy, heterocyclyl, cycloalkyl, heteroary or aryl, wherein the alkyl or alkoxy is optionally substituted with one or more (e.g. one, two or three) substituents selected from halogen, hydroxyl, thiol, cyano, amino, amido, nitro and SF 5 .
  • Substituted groups thus include for example Br, Cl, F, CN, Me, Et, Pr, t-Bu, OMe, OEt, OPr, C(CH 3 ) 3 , CH(CH 3 ) 2 , CF 3 , OCF 3 , C(O)NHCH 3 , cyclopropyl, phenyl, etc.
  • substitutions may be in the form of rings from adjacent carbon atoms in the aryl ring, for example cyclic acetals such as O-CH 2 -O.
  • the oxygen atom can be replaced with sulphur to make groups such as thio (SH) and thio-alkyl (S-alkyl).
  • Optional substituents therefore include groups such as S-methyl.
  • the sulphur atom may be further oxidised to make a sulfoxide or sulfone, and thus optional substituents therefore includes groups such as S(O)-alkyl and S(O) 2 -alkyl.
  • treat or “treating” or “treatment” includes prophylaxis and means to ameliorate, alleviate symptoms, eliminate the causation of the symptoms either on a temporary or permanent basis, or to prevent or slow the appearance of symptoms of the named disorder or condition.
  • the compounds of the invention are useful in the treatment of humans and non-human animals.
  • the dose of the compound is that amount effective to prevent occurrence of the symptoms of the disorder or to treat some symptoms of the disorder from which the patient suffers.
  • effective amount or “therapeutically effective amount” or “effective dose” is meant that amount sufficient to elicit the desired pharmacological or therapeutic effects, thus resulting in effective prevention or treatment of the disorder.
  • Prevention of the disorder is manifested by delaying the onset of the symptoms of the disorder to a medically significant extent.
  • Treatment of the disorder is manifested by a decrease in the symptoms associated with the disorder or an amelioration of the reoccurrence of the symptoms of the disorder.
  • Pharmaceutically acceptable salts of the compounds of the invention include but are not limited to addition salts (for example phosphates, nitrates, sulphates, borates, acetates, maleates, citrates, fumarates, succinates, methanesulphonates, benzoates, salicylates and hydrohalides), salts derived from organic bases (such as lithium, potassium and sodium), salts of amino acids (such as glycine, alanine, valine, leucine, isoleucine, cysteine, methionine and proline), inorganic bases (such as triethylamine, hydroxide, choline, thiamine and N-N'-diacetylethylenediamine).
  • Other pharmaceutically acceptable salts include ammonium salts, substituted ammonium salts and aluminium salts. Further pharmaceutically acceptable salts include quaternary ammonium salts of the compounds of the invention.
  • salts may be formed by conventional means, for example by reaction of a free acid or a free base form of a compound with one or more equivalents of an appropriate acid or base, optionally in a solvent, or in a medium in which the salt is insoluble, followed by removal of said solvent, or said medium, using standard techniques (e.g. in vacuo, by freeze-drying or by filtration). Salts may also be prepared by exchanging a counter-ion of a compound in the form of a salt with another counter-ion, for example using a suitable ion exchange resin.
  • the invention relates to these compounds prepared as isomeric mixtures or racemates whether present in an optically pure form or as mixtures with other isomers.
  • Enantiomers differ only in their ability to rotate plane-polarized light by equal amounts in opposite directions and are denoted as the (+) / ( S ) or (-) / ( R ) forms respectively.
  • Individual enantiomers or isomers may be prepared by methods known in the art, such as optical resolution of products or intermediates (for example chiral chromatographic separation e.g. chiral HPLC, or an asymmetric synthesis approach).
  • compounds of the invention exist as alternative tautomeric forms e.g. keto/enol, amide/imidic acid
  • the invention relates to the individual tautomers in isolation, and to mixtures of the tautomers in all proportions.
  • the compounds described herein may contain one or more isotopic substitutions, and a reference to a particular element includes within its scope all isotopes of the element.
  • a reference to hydrogen includes within its scope 1 H, 2 H (D), and 3 H (T).
  • references to carbon and oxygen include within their scope respectively 12 C, 13 C and 14 C and 16 O and 18 O.
  • isotopes include 2 H, 3 H, 11 C, 13 C, 14 C, 36 Cl, 18 F, 123 I, 125 I, 13 N, 15 N, 15 O, 17 O, 18 O, 32 P and 35 S.
  • a reference to a particular functional group also includes within its scope isotopic variations, unless the context indicates otherwise.
  • a reference to an alkyl group such as an ethyl group also covers variations in which one or more of the hydrogen atoms in the group is in the form of a deuterium or tritium isotope, e.g. as in an ethyl group in which all five hydrogen atoms are in the deuterium isotopic form (a perdeuteroethyl group).
  • Deuterium may be referred to throughout as "deutero".
  • the isotopes may be radioactive or non-radioactive.
  • the compounds contain no radioactive isotopes. Such compounds are preferred for therapeutic use.
  • the compounds may contain one or more radioisotopes. Compounds containing such radioisotopes may be useful in a diagnostic context.
  • Certain isotopically labelled compounds of formula (I), for example, those incorporating a radioactive isotope, are useful in drug and/or substrate tissue distribution studies.
  • the radioactive isotopes i.e. 3 H and 14 C are particularly useful for this purpose in view of their ease of incorporation and ready means of detection.
  • Substitution with heavier isotopes i.e. 2 H may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements, and hence may be preferred in some circumstances.
  • Substitution with positron emitting isotopes, such as 11 C, 18 F, 15 O and 13 N can be useful in Positron Emission Topography (PET) studies for examining receptor occupancy.
  • PET Positron Emission Topography
  • Isotopically labelled compounds of formula (I) can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying examples and preparations using an appropriate isotopically labelled reagent in place of the non-labelled reagent previously employed.
  • the compounds of formula (I) may exist in crystalline or amorphous form and some of the crystalline forms may exist as polymorphs, which are included within the scope of the present invention.
  • Polymorphic forms of compounds of formula (I) may be characterised and differentiated using a number of conventional analytical techniques, including, but not limited to, infra-red spectra, Raman spectra, X-ray powder diffraction, differential scanning calorimetry, thermogravimetric analysis and solid state nuclear magnetic resonance.
  • the invention provides a compound according to any described embodiments in a crystalline form.
  • the compound may be from 50% to 100% crystalline, and more particularly is at least 50% crystalline, or at least 60% crystalline, or at least 70% crystalline, or at least 80% crystalline, or at least 90% crystalline, or at least 95% crystalline, or at least 98% crystalline, or at least 99% crystalline, or at least 99.5% crystalline, or at least 99.9% crystalline, for example 100% crystalline.
  • the compound may alternatively be in an amorphous form.
  • the invention described herein relates to all crystal forms, solvates and hydrates of any of the disclosed compounds however so prepared. To the extent that any of the compounds disclosed herein have acid or basic centres such as carboxylates or amino groups, then all salt forms of said compounds are included herein. In the case of pharmaceutical uses, the salt should be seen as being a pharmaceutically acceptable salt.
  • the invention relates to any solvates of the compounds and their salts.
  • Preferred solvates are solvates formed by the incorporation into the solid state structure (e.g. crystal structure) of the compounds of the invention of molecules of a non-toxic pharmaceutically acceptable solvent (referred to below as the solvating solvent).
  • solvents include water, alcohols (such as ethanol, isopropanol and butanol) and dimethylsulfoxide.
  • Solvates can be prepared by recrystallising the compounds of the invention with a solvent or mixture of solvents containing the solvating solvent.
  • Whether or not a solvate has been formed in any given instance can be determined by subjecting crystals of the compound to analysis using well known and standard techniques such as thermogravimetric analysis (TGE), differential scanning calorimetry (DSC) and X-ray crystallography.
  • TGE thermogravimetric analysis
  • DSC differential scanning calorimetry
  • X-ray crystallography X-ray crystallography
  • the solvates can be stoichiometric or non-stoichiometric solvates.
  • Particular solvates may be hydrates, and examples of hydrates include hemihydrates, monohydrates and dihydrates.
  • solvates and the methods used to make and characterise them see Bryn et al., Solid-State Chemistry of Drugs, Second Edition, published by SSCI, Inc of West Lafayette, IN, USA, 1999, ISBN 0-967-06710-3 .
  • compositions as defined herein including ester derivatives and/or derivatives that have, or provide for, the same biological function and/or activity as any relevant compound of the invention.
  • derivatives include prodrugs of compounds as defined herein.
  • prodrug of a relevant compound includes any compound that, following oral or parenteral administration, is metabolised in vivo to form that compound in an experimentally-detectable amount, and within a predetermined time (e.g. within a dosing interval of between 6 and 24 hours (i.e. once to four times daily).
  • Prodrugs of compounds may be prepared by modifying functional groups present on the compound in such a way that the modifications are cleaved, in vivo when such prodrug is administered to a mammalian subject. The modifications typically are achieved by synthesizing the parent compound with a prodrug substituent.
  • Prodrugs include compounds wherein a hydroxyl, amino, sulfhydryl, carboxyl or carbonyl group in a compound is bonded to any group that may be cleaved in vivo to regenerate the free hydroxyl, amino, sulfhydryl, carboxyl or carbonyl group, respectively.
  • prodrugs include, but are not limited to, esters and carbamates of hydroxyl functional groups, ester groups of carboxyl functional groups, N-acyl derivatives and N-Mannich bases. General information on prodrugs may be found e.g. in Bundegaard, H. "Design of Prodrugs” p. 1-92, Elsevier, New York-Oxford (1985 ).
  • Compounds of the invention may be metabolised in vivo.
  • the term 'metabolites' refers to all molecules derived from any of the compounds according to the present invention in a cell or organism, preferably mammal.
  • the term relates to molecules which differ from any molecule which is present in any such cell or organism under physiological conditions.
  • a treatment defined herein may be applied as a sole therapy of may involve, in addition to the compounds of the invention, conventional surgery or radiotherapy or chemotherapy.
  • compounds of formula (I) can also be used in combination with existing therapeutic agents for the treatment of conditions associated with cancer, including small molecule therapeutics or antibody based therapeutics.
  • the compounds of the invention are characterised by a 8 membered bicyclic ring structure which is formed from a cyanopyrrolidine core fused to a 5 membered aromatic ring, wherein the aromatic ring contains at least one nitrogen heteroatom.
  • a compound of formula I a tautomer thereof, or a pharmaceutically acceptable salt of said compound or tautomer, wherein:
  • Ring A contains from 1 to 3 nitrogen atoms. In one embodiment, ring A contains one nitrogen atom. In one embodiment, ring A contains two nitrogen atoms. In another embodiment, ring A contains three nitrogen atoms. Preferably, ring A contains two nitrogen atoms.
  • Ring A may be selected from the following structures and tautomers thereof:
  • the fused aromatic ring is: or a tautomer thereof.
  • * represents the ring atoms shared with the cyanopyrrolidine core to form a 8 membered bicyclic ring.
  • the ring may be substituted with -Q 1 -B and (-Q 2 -(D) m ) n , wherein Q 1 , Q 2 , B, D, m and n are as defined herein.
  • R 1a , R 1b , R 1c and R 1d may each independently represent hydrogen, optionally substituted C 1 -C 6 alkyl, or R 1a together with R 1b forms a C 3 -C 6 cycloalkyl, or R 1c and together with R 1d form a C 3 -C 6 cycloalkyl.
  • R 1a , R 1b , R 1c and R 1d may each independently represent hydrogen or C 1 -C 3 alkyl (e.g. methyl or ethyl).
  • R 1a may be hydrogen or C 1 -C 3 alkyl and R 1b may be hydrogen.
  • R 1c may be hydrogen or C 1 -C 3 alkyl and R 1d may be hydrogen.
  • R 1a , R 1b , R 1c and R 1d each represent hydrogen.
  • the alkyl within the definitions of R 1a , R 1b , R 1c and R 1d may be unsubstituted or substituted with one or more substituents selected from halogen, hydroxyl, and cyano.
  • the alkyl may be substituted with fluorine.
  • R 1a may represent hydrogen.
  • R 1a may represent C 1 -C 6 alkyl.
  • R 1a may represent C 1 -C 3 alkyl, for example, methyl or ethyl.
  • R 1b , R 1c and R 1d may each represent hydrogen.
  • the alkyl within the definition of R 1a may be unsubstituted or substituted with one or more substituents selected from halogen, hydroxyl, and cyano. In particular, the alkyl may be substituted with fluorine.
  • R 1b may represent hydrogen.
  • R 1b may represent C 1 -C 6 alkyl.
  • R 1b may represent C 1 -C 3 alkyl, for example, methyl or ethyl.
  • R 1a , R 1c and R 1d may each represent hydrogen.
  • the alkyl within the definition of R 1b may be unsubstituted or substituted with one or more substituents selected from halogen, hydroxyl, and cyano. In particular, the alkyl may be substituted with fluorine.
  • R 1c may represent hydrogen.
  • R 1c may represent C 1 -C 6 alkyl.
  • R 1c may represent C 1 -C 3 alkyl, for example, methyl or ethyl.
  • R 1a , R 1b and R 1d may each represent hydrogen.
  • the alkyl within the definition of R 1c may be unsubstituted or substituted with one or more substituents selected from halogen, hydroxyl, and cyano. In particular, the alkyl may be substituted with fluorine.
  • R 1d may represent hydrogen.
  • R 1d may represent C 1 -C 6 alkyl.
  • R 1d may represent C 1 -C 3 alkyl, for example, methyl or ethyl.
  • R 1a , R 1b and R 1c may each represent hydrogen.
  • the alkyl within the definition of R 1d may be unsubstituted or substituted with one or more substituents selected from halogen, hydroxyl, and cyano. In particular, the alkyl may be substituted with fluorine.
  • R 1a and R 1c may together form a cycloalkyl ring.
  • R 1c and R 1d may together form a cycloalkyl ring.
  • R 1a and R 1b together form a cycloalkyl ring
  • R 1c and R 1d may each independently represent hydrogen or optionally substituted C 1 -C 6 alkyl.
  • R 1a and R 1b may each independently represent hydrogen or optionally substituted C 1 -C 6 alkyl.
  • the cycloalkyl ring within the definitions of R 1a , R 1b , R 1c and R 1d can contain 3, 4, 5, or 6 carbon ring atoms, in particular 3 or 4 carbon ring atoms.
  • the cycloalkyl ring is attached to the cyanopyrrolidine core as a spiro ring, i.e. they share one ring atom.
  • the compounds may be in the form where R 1a , R 1b , R 1c and R 1d are each hydrogen. In such cases the compounds may be of the formula: wherein ising, p, q, R 8 , R 9 and R 10 are as defined before.
  • p is 0 or 1 and q is 0 or 1 wherein p and q are not both 0 and only one of p and q is 1, i.e. p and q cannot both be 1.
  • p is 1 and q is 0.
  • R 8 may represent -Q 1 -B, wherein Q 1 and B are as defined herein and R 10 may be hydrogen or -Q 2 -(D) m wherein m is 0 or 1 and Q 2 and D are as defined herein.
  • R 10 may be hydrogen or -Q 2 -(D) m wherein m is 0 and Q 2 is as defined herein.
  • R 10 may be -Q 2 -(D) m wherein m is 1 and Q 2 and D are as defined herein.
  • R 8 may represent hydrogen or -Q 2 -(D) m wherein m is 0 or 1 and Q 2 and D are as defined herein and R 10 represents -Q 1 -B wherein Q 1 and B are as defined herein.
  • R 8 may represent hydrogen or -Q 2 -(D) m wherein m is 0 and Q 2 is as defined herein.
  • R 8 may represent -Q 2 -(D) m wherein m is 1 and Q 2 and D are as defined herein.
  • p is 0 and q is 1.
  • R 9 represents hydrogen or optionally substituted C 1 -C 6 alkyl and R 10 represents -Q 1 -B wherein Q 1 and B are as defined herein.
  • the alkyl may be substituted with halogen, hydroxyl, or cyano.
  • R 9 is hydrogen or methyl. More particularly, R 9 is methyl.
  • Q 1 may be selected from a covalent bond, an oxygen atom, a sulphur atom, -OR 4 -, -SO-, -SO 2 -, -C(O)-, -C(O)O-, -C 0 -C 3 -alkylene-C(O)NR 2 -C 0 -C 3 -alkylene, -C 0 -C 3 -alkylene-NR 2 -C 0 -C 3 -alkylene (e.g.
  • R 2 and R 3 each independently represent hydrogen or C 1 -C 6 alkyl, C 1 -C 4 alkyl, or C 1 -C 2 alkyl.
  • the alkyl may be optionally substituted with halogen, hydroxyl, or cyano.
  • R 4 represents C 1 -C 6 alkylene, C 1 -C 4 alkylene or C 1 -C 2 akylene.
  • the alkylene may be optionally substituted with halogen, hydroxyl, or cyano.
  • Q 1 may be selected from a covalent bond, -C 0 -C 3 alkylene-NR 2 C(O)-C 0 -C 3 alkylene, - C 0 -C 3 -alkylene-NR 2 -C 0 -C 3 -alkylene or optionally substituted -C 1 -C 6 alkylene, and R 2 represents hydrogen or C 1 -C 3 alkyl wherein the alkyl may be unsubstituted or substituted with halogen, hydroxyl, or cyano.
  • Q 1 is selected from a covalent bond, C 1 alkylene-NHC(O)-, -NH-, methylene or methylene-NHC(O)-methylene. In another embodiment, Q 1 is a covalent bond.
  • B represents an optionally substituted 5 to 10 membered (e.g. 5, 6, 7, 8, 9, or 10 membered) monocyclic or bicyclic aryl or heteroaryl ring.
  • B may represents an optionally substituted 5 or 6 membered monocyclic aryl or heteroaryl ring.
  • B may represent an optionally substituted 9 or 10 membered bicyclic aryl or heteroaryl ring.
  • B may be selected from naphthyl, naphthalenyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, furyl, pyrrolyl, oxazolyl, thiazolyl, pyrazolyl, tetrazolyl, indolyl, indolizinyl, isoindolyl, indolinyl, purinyl, furazanyl, imidazolyl, indazolyl, isothiazolyl, isoxazolyl, oxadiazolyl, tetrazolyl, thiadiazolyl, benzofuranyl, isobenzofuranyl, benzothiophenyl, isobenzothiophenyl, benzimidazolyl, benzothiazolyl, napthyridinyl, pteridinyl, pyrazinyl, quinolinyl, isoquinoliny
  • B is selected from phenyl, quinolinyl, pyridinyl, pyrazolyl, indazolyl, imidazolyl and isoquinolinyl. More particularly, B is phenyl.
  • B may be selected from phenyl, indazolyl or pyrazolyl.
  • B may be indazolyl.
  • B may be unsubstituted or substituted with one to four (e.g. one, two three or four) substituents selected from halogen, cyano, oxo, hydroxyl, -SR 11 , optionally substituted -C 1 -C 6 alkyl, optionally substituted -C 1 -C 6 alkoxy, optionally substituted -C 2 -C 6 alkenyl, optionally substituted -C 2 -C 6 alkynyl, -Q 3a -R 13 , -Q 3a -O-Q 3b -R 13 , -Q 3a -S-Q 3b -R 13 , -Q 3a -SO-Q 3b -R 13 , -Q 3a -NR 11 CONR 12 R 12a , -Q 3a -NR 11 CONR 12 -Q 3a -NR 11 CONR 12 -Q 3a -R 13 , -Q 3a -NR 11 R 12 ,
  • Q 3a and Q 3b each independently represent a covalent bond, C 1 -C 6 alkylene, C 1 -C 4 alkylene, C 1 -C 2 alkylene or C 2 -C 6 alkenylene or C 2 -C 4 alkenylene.
  • the alkylene or alkenylene may be substituted with halogen, hydroxyl, or cyano.
  • R 11 , R 12 and R 12a each independently represent hydrogen or C 1 -C 6 alkyl, C 1 -C 4 alkyl or C 1 -C 2 alkyl.
  • the alkyl may be substituted with halogen, hydroxyl, or cyano.
  • R 13 represents optionally substituted heterocyclyl, optionally substituted heteroaryl, optionally substituted aryl, or an optionally substituted cycloalkyl.
  • the substituents may be selected from halogen, cyano, oxo, hydroxyl, -SR 11 , optionally substituted -C 1 -C 6 alkyl, optionally substituted -C 1 -C 6 alkoxy, optionally substituted -C 2 -C 6 alkenyl, optionally substituted -C 2 -C 6 alkynyl, -Q 3a -NR 11 CONR 12 R 12a , -Q 3a -NR 11 R 12 , -Q 3a -COR 11 ,-Q 3a -NR 11 COR 12 , -Q 3a -NR 11 C(O)OR 12 , -Q 3a -SO 2 R 11 , -Q 3a -CONR 11 R 12 , -Q 3a -CO 2 R 11 , -Q 3a -SO 2 NR 11 R 12 , -Q 3a -NR 11 SO 2 R 12 and -Q 3a -NR 11 SO 2 NR 12
  • B may be substituted with one to four, in particular only one, ring substituents which may be selected from -Q 3a -R 13 , -Q 3a -O-Q 3b -R 13 , -Q 3a -S-Q 3b -R 13 , -Q 3a -SO-Q 3b -R 13 , -Q 3a -NR 11 CONR 12 -Q 3a -R 13 , -Q 3a -NR 11 -Q 3b -R 13 , -Q 3a -CO-Q 3b -R 13 , -Q 3a -NR 11 CO-Q 3b -R 13 , -Q 3a -SO 2 -Q 3b -R 13 , -Q 3a -CONR 11 -Q 3b -R 13 , -Q 3a -CO 2 -Q 3b -R 13 , -Q 3a -SO 2 NR 11 -Q 3b -R 13
  • B may be substituted with one to four substituents selected from halogen, cyano, optionally substituted C 1 -C 6 alkyl, optionally substituted C 1 -C 6 alkoxy, -Q 3a -R 13 , -Q 3a -O-Q 3b -R 13 , -Q 3a -CONR 11 R 12 , -Q 3a -CONR 11 -Q 3b -R 12 , -Q 3a -NR 11 CO-Q 3b -R 13 , -Q 3a -SO 2 NR 11 R 12 , -Q 3a -SO 2 NR 11 -Q 3b -R 13 and -Q 3a -NR 11 SO 2 -Q 3b -R 13 .
  • substituents selected from halogen, cyano, optionally substituted C 1 -C 6 alkyl, optionally substituted C 1 -C 6 alkoxy, -Q 3a -R 13 , -Q 3a
  • Q 3a is a covalent bond or optionally substituted C 1 -C 3 alkylene.
  • Q 3a may be a covalent bond, methylene or ethylene.
  • Q 3b is a covalent bond or optionally substituted C 1 -C 3 alkylene.
  • Q 3b may be a covalent bond, methylene or ethylene.
  • R 11 , R 12 and R 12a each independently represent hydrogen or optionally substituted C 1 -C 3 alkyl.
  • the optional substituents for the alkyl may be selected from halogen, hydroxyl, and cyano. In particular the optional substituents are selected from fluorine.
  • R 13 may be an optionally substituted 3 to 10 membered monocyclic or bicyclic heterocyclyl, heteroaryl, cycloalkyl or aryl ring.
  • R 13 may be a 3 to 6 membered ring.
  • R 13 may be a 9 or 10 membered ring.
  • R 13 may unsubstituted or substituted with one to four substituents selected from halogen, hydroxyl, thiol, cyano, amino, amido, nitro, SF 5 , C 1 -C 3 alkyl or C 1 -C 3 alkoxy. In one embodiment, R 13 is unsubstituted. More particularly, R 13 is an unsubstituted or substituted monocyclic 3 or 6 membered heterocyclyl, heteroaryl, cycloalkyl or aryl ring.
  • the ring may be unsubstituted or substituted with halogen, hydroxyl, thiol, cyano, amino, amido, nitro, SF 5 , C 1 -C 3 alkyl or C 1 -C 3 alkoxy. More particularly, R 13 is unsubstituted or mono-substituted. More particularly, R 13 is unsubstituted or substituted with C 1 -C 3 alkyl.
  • R 13 may be an optionally substituted 3 to 6 membered monocyclic heterocyclyl, heteroaryl, cycloalkyl or aryl ring.
  • R 13 may be selected from phenyl, pyridinyl, piperazinyl and cyclopropyl.
  • R 13 may be selected from phenyl or cyclopropyl.
  • the optional substituents for the alkyl and alkoxy within the definitions of B and R 11 , R 12 and R 12a may be selected from halogen, hydroxyl, and cyano.
  • the optional substituents are fluorine.
  • B may be substituted with one to four substituents selected from fluorine; chlorine; cyano; methyl; propyl; CF 3 ; methoxy; propoxy; OCF 3 ; -C(O)NH 2 , -C(O)NHCH 3 , - C(O)N(CH 3 ) 2 (i.e. -Q 3a -C(O)R 11 R 12 wherein Q 3a is a covalent bond and R 11 and R 12 are each indpendently hydrogen or methyl); -SO 2 N(CH 3 ) 2 (i.e.
  • B may be unsubstituted or substituted with halogen, C 1 -C 6 alkoxy, -CONR 11 R 12 or -Q 3a -R 13 , wherein R 11 , R 12 , R 13 and Q 3a are as defined herein.
  • B may be substituted with fluorine, methyl, methoxy, -C(O)NH 2 , -C(O)NHMe, Q 3a -phenyl wherein Q 3a is a covalent bond or -CONH-C 1 -C 2 alkylene.
  • B is unsubstituted or substituted with Q 3a -phenyl wherein Q 3a is -CONH-C 1 alkylene.
  • B is unsubstituted, mono-substituted, di-substituted or tri-substituted.
  • B is unsubstituted, mono-substituted or di-substituted.
  • B is unsubstituted or mono-substituted.
  • B is unsubstituted.
  • B is selected from phenyl, naphthyl, naphthalenyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, furyl, pyrrolyl, oxazolyl, thiazolyl, pyrazolyl, tetrazolyl, indolyl, indolizinyl, isoindolyl, indolinyl, purinyl, furazanyl, imidazolyl, indazolyl, isothiazolyl, isoxazolyl, oxadiazolyl, tetrazolyl, thiadiazolyl, benzofuranyl, isobenzofuranyl, benzothiophenyl, isobenzothiophenyl, benzimidazolyl, benzothiazolyl, napthyridinyl, pteridinyl, pyrazinyl, quinolinyl
  • B may represent a ring selected from phenyl, quinolinyl, pyridinyl, pyrazolyl, indazolyl, imidazolyl and isoquinolinyl which may be unsubstituted or substituted with one to four substituents selected from halogen, cyano, oxo, hydroxyl, -SR 11 , optionally substituted -C 1 -C 6 alkyl, optionally substituted -C 1 -C 6 alkoxy, optionally substituted -C 2 -C 6 alkenyl, optionally substituted -C 2 -C 6 alkynyl, -Q 3a -R 13 , -Q 3a -O-Q 3b -R 13 , -Q 3a -S-Q 3b -R 13 , -Q 3a -SO-Q 3b -R 13 , -Q 3a -NR 11 CONR 12 R 12a , -Q 3a -NF 11
  • B may represent a ring selected from quinolinyl, pyridinyl, pyrazolyl, indazolyl, imidazolyl and isoquinolinyl which may which may unsubstituted or substituted with one to four (e.g.
  • substituents selected from fluorine, chlorine, cyano, methyl, propyl, CF 3 , methoxy, propoxy, OCF 3 , -C(O)NH 2 , -C(O)NHCH 3 , -C(O)N(CH 3 ) 2 , -SO 2 N(CH 3 ) 2 , -R 13 , -C(O)NH-R 13 , -C(O)NH-methylene-R 13 , -C(O)NH-ethylene-R 13 , -O-methylene-R 13 , -O-R 13 , -C(O)-R 13 , methylene-R 13 ,-SO 2 NH-R 13 , -NHSO 2 -R 13 , -NHSO 2 -R 13 , wherein R 13 is selected from phenyl, pyridinyl, piperazinyl and cyclopropyl.
  • Q 2 represents halogen, cyano, nitro, hydroxyl, -SR 5 , -NR 5 R 6 , -CONR 5 R 6 ,-C 0 -C 3 -alkylene-NR 5 COR 6 , -NR 5 CONR 6 R 6a , -COR 5 , -C(O)OR 5 , -SO 2 R 5 , -SO 2 NR 5 R 6 , -NR 5 SO 2 R 6 ,-NR 4 SO 2 NR 6 R 6a , -NR 5 C(O)OR 6 , optionally substituted -C 1 -C 6 alkyl, optionally substituted C 1 -C 6 alkoxy, optionally substituted -C 2 -C 6 alkenyl, a covalent bond, an oxygen atom, a sulphur atom,-OR 7 -, -SO-, -SO 2 -, -CO-, -C(O)O-, -C 0
  • Q 2 represents optionally substituted C 1 -C 6 alkyl, -C 0 -C 3 -alkylene-NR 5 COR 6 , a covalent bond, C 1 -C 6 alkylene, -C 0 -C 3 -alkylene-NR 5 -C 0 -C 3 alkylene or -C 0 -C 3 -alkylene-NR 5 C(O)-C 0 -C 3 alkylene, wherein R 5 is hydrogen or C 1 -C 3 alkyl.
  • Q 2 represents methyl, i-propyl, -NHC(O)CH 3 , a covalent bond, methylene, -NH- or methylene-NR 5 C(O)-.
  • D represents an optionally substituted 3 to 10 membered monocyclic or bicyclic heterocyclyl, heteroaryl, cycloalkyl or aryl ring (when m is 0, Q 2 is present and D is absent).
  • D may represent an optionally 5 or 6 membered monocyclic heterocyclyl, heteroaryl or aryl ring.
  • D may represent an optionally substituted 9 or 10 membered bicyclic heterocyclyl, heteroaryl or aryl ring.
  • D may be selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, decahydronaphthalenyl, phenyl, naphthyl, naphthalenyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, furyl, pyrrolyl, oxazolyl, thiazolyl, pyrazolyl, tetrazolyl, indolyl, indolizinyl, isoindolyl, indolinyl, purinyl, furazanyl, imidazolyl, indazolyl, isothiazolyl, isoxazolyl, oxadiazolyl, tetrazolyl, thiadiazolyl, benzofuranyl, isobenzofuranyl, benzothiophenyl
  • D is selected from phenyl, isoquinolinyl and pyridinyl. More particularly, D is phenyl.
  • D may be unsubstituted or substituted with one to four (e.g. one, two three or four) substituents selected from optionally substituted -C 1 -C 6 alkyl, optionally substituted -C 1 -C 6 alkoxy, and -CONR 14 R 15 ;
  • R 14 , R 15 each independently represent hydrogen or optionally substituted C 1 -C 6 alkyl.
  • D may be unsubstituted or substituted with methyl, i-propyl, methoxy or - C(O)NH 2 .
  • the optional substituents for the alkyl and alkoxy within the definitions of D and R 14 , R 15 and R 15a may be selected from halogen, hydroxyl, and cyano.
  • the optional substituents are fluorine.
  • D is unsubstituted, mono-substituted, di-substituted or tri-substituted.
  • D is unsubstituted, mono-substituted or di-substituted.
  • D is unsubstituted or mono-substituted.
  • D is unsubstituted.
  • D is selected from phenyl, naphthyl, naphthalenyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, furyl, pyrrolyl, oxazolyl, thiazolyl, pyrazolyl, tetrazolyl, indolyl, indolizinyl, isoindolyl, indolinyl, purinyl, furazanyl, imidazolyl, indazolyl, isothiazolyl, isoxazolyl, oxadiazolyl, tetrazolyl, thiadiazolyl, benzofuranyl, isobenzofuranyl, benzothiophenyl, isobenzothiophenyl, benzimidazolyl, benzothiazolyl, napthyridinyl, pteridinyl, pyrazinyl, quinolinyl
  • D may represent a ring selected from phenyl, isoquinolinyl and pyridinyl which may be unsubstituted or substituted with one four substituents selected from optionally substituted -C 1 -C 6 alkyl, optionally substituted -C 1 -C 6 alkoxy, and -CONR 14 R 15 ;
  • R 14 R 15 each independently represent hydrogen or optionally substitued C 1 -C 6 alkyl.
  • D may represent a ring selected from phenyl, isoquinolinyl and pyridinyl which may which may unsubstituted or substituted with one to four (e.g. one, two or three) substituents selected from optionally substituted C 1 -C 6 alkyl, optionally substituted C 1 -C 6 alkoxy and -CONR 14 R 15 wherein R 14 and R 15 each independently represent hydrogen or optionally substituted C 1 -C 6 alkyl.
  • novel compounds of formula I include:
  • a process for the preparation of a compound of formula I or a pharmaceutically acceptable salt thereof, or a compound of formula II or a pharmaceutically acceptable salt thereof comprising the steps of reacting an amine of formula III or formula IV respectively with cyanogen bromide to form N-CN compounds:
  • R 1a , R 1b , R 1c , R 1d and A are as defined herein.
  • R 1a , R 1b , R 1c , R 1d , R 8 , R 9 , R 10 p and q are as defined herein.
  • composition comprising a compound of the invention.
  • the compounds of the invention may be used in the treatment of disorders and diseases related to DUB or desumoylation inhibition, particularly USP7.
  • a compound of formula (I) or pharmaceutical composition thereof for use in therapy there is provided a compound of formula (I) or pharmaceutical composition thereof for use in therapy.
  • the compounds of the invention have use in the treatment of cancer and more particularly in the treatment of cancer linked to DUB or desumoylation activity.
  • Compounds of the invention may be useful against any DUB or desumoylating enzyme, including but not limited to USP7, USP30, USP47, SENP2 and SENP6.
  • the compounds described herein may be used in the manufacture of a medicament for the treatment of cancer linked to DUB or desumoylation activity.
  • a method of treatment or prevention of cancer linked to USP7 activity comprising administering a pharmaceutically effective amount of a compound of the invention or a pharmaceutical composition thereof to an individual suffering from cancer linked to USP7 activity.
  • cancer or “tumour” include but are not limited to breast, ovarian, prostate, lung, kidney, gastric, colon, testicular, head and neck, pancreas, brain, melanoma, bone, liver, soft tissue or other cancers of tissue organs and cancers of the blood cells such as lymphomas and leukaemias.
  • cancers include lymphoma, multiple myeloma, CML, AML, mantle cell lymphoma, neuroblastoma, colorectal cancer, melanoma, soft tissue sarcomas including liposarcoma, fibroblastic sarcoma and leiomyosarcoma, hepatocellular carcinoma, osteosarcoma, oesophageal cancer and non-small cell lung carcinoma.
  • the compounds or compositions disclosed herein may be used to treat additional diseases linked to USP7 activity.
  • the compounds of the invention or pharmaceutical compositions thereof as described herein may be combined with one or more additional agents.
  • the compounds may be combined with one or more additional anti-tumour therapeutic agents, for example chemotherapeutic drugs immune checkpoint inhibitors or inhibitors of other regulatory proteins.
  • the one or more anti-tumour agent is a chemotherapeutic agent.
  • Chemotherapeutic agents may be selected from olaparib, mitomycin C, cisplatin, carboplatin, oxaliplatin, ionizing radiation (IR), camptothecin, irinotecan, topotecan, temozolomide, taxanes, 5-fluoropyrimidines, gemcitabine, and doxorubicin.
  • the additional anti-tumour therapeutic agent is a BH-3 mimetic.
  • BH-3 mimetics may be selected from but not limited to one or more of ABT-737, ABT-199, ABT-263, and Obatoclax.
  • the compounds of the invention may be useful in the treatment of disorders and diseases related to USP30 inhibition.
  • the compounds of the invention may therefore be useful in the treatment of disorders or diseases having a component relating to mitochondrial dysfunction.
  • Mitochondria are specialized subcellular organelles required for energy production in the form of ATP. In the case of mitochondrial dysfunction, cells cannot produce sufficient ATP resulting in cell injury or death. Diseases of the mitochondria appear most often in organs that are very energy demanding such as the brain, heart, liver, skeletal muscles, kidney and the endocrine and respiratory system.
  • the condition involving mitochondrial dysfunction may be selected from a condition involving a mitophagy defect, a condition involving a mutation in mitochondrial DNA, a condition involving mitochondrial oxidative stress, a condition involving a defect in mitochondrial membrane potential, mitochondrial biogenesis, a condition involving a defect in mitochondrial shape or morphology, and a condition involving a lysosomal storage defect.
  • the condition involving mitochondrial dysfunction may be selected from a neurodegenerative disease; multiple sclerosis (MS), mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) syndrome; Leber's hereditary optic neuropathy (LHON); cancer; neuropathy, ataxia, retinitis pigmentosa-maternally inherited Leigh syndrome (NARP-MILS); Danon disease; diabetes; diabetic nephropathy; metabolic disorders; heart failure; ischemic heart disease leading to myocardial infarction; psychiatric diseases, for example schizophrenia; multiple sulfatase deficiency (MSD); mucolipidosis II (ML II); mucolipidosis III (ML III); mucolipidosis IV (ML IV); GMl-gangliosidosis (GM1); neuronal ceroid-lipofuscinoses (NCL1); Alpers disease; Barth syndrome; Beta-oxidation defects; carnitine-acyl-carni
  • the condition involving mitochondrial dysfunction may be a CNS disorder, for example a neurodegenerative disease.
  • Neurodegenerative diseases include, but are not limited to, Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), Huntington's disease, ischemia, stroke, dementia with Lewy bodies, and frontotemporal dementia.
  • compositions of the invention may be designed for administration by the oral, parenteral or mucosal route and the choice or the specific form of composition is dependent on the administration route.
  • the composition may be in the form, for example, of tablets, lozenges, dragees, films, powders, elixirs, syrups, liquid preparations including dispersions, suspensions, emulsions, solutions or sprays, cachets, granules, capsules, etc.
  • the composition may be in the form of sprays, inhalants, dispersions, suspensions, emulsions, solutions, gels, patches, films, ointments, creams, lotions, suppositories etc.
  • parenteral administration the composition is in the form of a liquid preparation such as a solution, dispersion, emulsion or suspension including liposome compositions.
  • Preparations according to the invention for parenteral administration include sterile aqueous, aqueous-organic, and organic solutions, suspensions and emulsions.
  • Such dosage forms are prepared according to techniques known in the art of pharmaceutical formulation.
  • the pharmaceutical compositions When in the form of sprays or inhalants the pharmaceutical compositions may be administered nasally. Suitable formulations for this purpose are known to those skilled in the art.
  • compositions of the invention may be administered by injection and may be in the form of a sterile liquid preparation for injection, including liposome preparations.
  • the pharmaceutical compositions of the invention may also be in the form of suppositories for rectal administration. These are formulated so that the pharmaceutical composition is solid at room temperature and liquid at body temperature to allow release of the active compound.
  • the dosages may be varied depending upon the requirements of the patient, the severity of the condition being treated, and the compound being employed. Determination of the proper dosage for a particular situation is within the remit of the person skilled in the skill of the art. Generally, treatment is initiated with smaller dosages which are less than the optimal dose of the compound. Thereafter the dosage is increased by small increments until the optimum effect under the circumstances is reached.
  • the magnitude of an effective dose of a compound will, of course, vary with the nature of the severity of the condition to be treated and with the particular compound and its route of administration. The selection of appropriate dosages is within the ability of one of ordinary skill in this art, without undue burden.
  • the daily dose range is about 10 ⁇ g to about 100 mg per kg body weight of a human and non-human animal and in general may be around 10 ⁇ g to 30mg per kg body weight per dose. The above dose may be given from one to three times per day.
  • Compounds of the invention may be prepared via a variety of synthetic routes. Exemplary routes to certain compounds of the invention are shown below. Representative compounds of the present invention can be synthesized in accordance with the general synthetic methods described below and are illustrated more particularly in the schemes that follow. Since the schemes are an illustration, the invention should not be construed as being limited by the chemical reactions and conditions expressed. The preparation of the various starting materials used in the schemes is well within the skill of persons versed in the art. Those skilled in the art appreciate that, where appropriate, the individual transformations within a scheme can be completed in a different order. The following schemes describe general synthetic methods whereby intermediate and target compounds of the present invention may be prepared.
  • Step a To a solution of 4-bromo-1H-imidazole ( CAS Number 2302-25-2 , available from Combi blocks) (5.0 g, 34.01 mmol) in MeOH (10 ml) were added phenylboronic acid (10.36 g, 85.03 mmol), NaOH (2.04 g, 51.0 mmol) and copper(II)chloride (0.55 g, 4.08 mmol) at rt. The reaction mixture was purged with oxygen. The resulting reaction mixture was heated at 65°C for 3 h with continuous slow oxygen purging. The resulting reaction mixture was cooled to rt, poured into water (30 ml) and extracted with EtOAc (6 x 20 ml).
  • Step b To a solution of 4-bromo-1-phenyl-1H-imidazole (2.0 g, 9.010 mmol) in 1,4-dioxane (5 ml) were added di-tert-butyl hydrazinodicarboxylate (1.84 g, 8.144 mmol), N,N-dimethylethylenediamine (0.16g, 1.809 mmol), K 3 PO 4 (7.67 g, 36.198 mmol) and CuI (0.34 g, 1.809 mmol) at rt. The resulting reaction mixture was heated at 100°C for 3 h. The resulting reaction mixture was poured into water (20 ml) and extracted with EtOAc (4 x 20 ml).
  • Step c Di-tert-butyl 1-(1-phenyl-1H-imidazol-4-yl)hydrazine-1,2-dicarboxylate (1.15 g, 3.073 mmol) was stirred in 4M HCl in 1,4-dioxane (5 ml) at rt for 30 min. The resulting reaction mixture was concentrated under reduced pressure yielding 4-hydrazinyl-1-phenyl-1H-imidazole HCl salt (1.15 g, quantitative). LCMS: Method 1, 1.507 min, MS: ES+ 175.19.
  • Step a To a solution of 4-nitro-1H-pyrazole ( CAS Number 2075-46-9 available from Combi Blocks) (4.000 g, 35.4 mmol) in MeOH (30 ml) was added phenylboronic acid (7.700 g, 63.7 mmol). TEA (1.43 g, 14.16 mmol) was added to the reaction mixture at rt. The reaction mixture was purged with oxygen for 15 min at rt. Cu 2 O (0.500 g, 3.506 mmol) was added to the reaction mixture. The reaction mixture was heated at 65°C for 34 h with continuous purging of oxygen.
  • Step b To a solution of 4-nitro-1-phenyl-1H-pyrazole (0.600 g, 3.174 mmol) in EtOH:water (1:1, 10 ml) was added Fe powder (0.495 g, 9.52 mmol). AcOH (0.942 g, 15.7 mmol) was added to the reaction mixture at rt. The reaction mixture was heated at 80°C for 2 h. The resulting reaction mixture was cooled to rt, filtered through celite bed and washed with MeOH (2 x 10 ml). The combined filtrate was concentrated under reduced pressure yielding 1-phenyl-1H-pyrazol-4-amine (0.500 g, 3.144 mmol). LCMS: Method 1, 1.341 min, MS: ES+ 160.14. This material was used directly for the next step without further purification.
  • Step c To a solution of 1-phenyl-1H-pyrazol-4-amine (0.500 g, 3.144 mmol) in concentrated HCl (5 ml) was added solution of NaNO 2 (0.260 g, 3.768 mmol) in water (2 ml) at 0°C. The resulting reaction mixture was stirred at 0°C for 1 h. A solution of SnCl 2 .2H 2 O (1.780 g, 9. 418 mmol) in concentrated HCl (5 ml) was added to the above reaction mixture at 0°C. The resulting reaction mixture was stirred at rt for 2 h.
  • Step a To a solution of 4-bromo-3-fluoroaniline (CAS Number 656-65-5 ; 1.000 g, 5.292 mmol) in EtOH (30 ml) were added TEA (2.21 ml, 15.9 mmol) followed by chlormethine hydrochloride (CAS Number 55-86-7 ; 2.037 g, 10.58 mmol) at rt. The reaction mixture was heated at 100°C for 18 h. The reaction mixture was combined with one other batch prepared on the same scale by an identical method. The resulting mixture was cooled to rt, filtered and the filtrate was concentrated under reduced pressure.
  • Step b To a stirred solution of 1-(4-bromo-3-fluorophenyl)-4-methylpiperazine (0.680 g, 2.50 mmol) in toluene (30 ml) were added K 2 CO 3 (0.690 g, 5.00 mmol) and bispinacolatodiboron (0.950 g, 3.75 mmol) at rt. The reaction mixture was degassed for 10 min before addition of Pd(PPh 3 ) 4 (0.289 g, 0.250 mmol) at rt. The reaction mixture was heated at 100°C for 8 h. The resulting mixture was cooled to rt, filtered under vacuum and the filtrate was concentrated under reduced pressure.
  • Reagents and conditions a) Ar-NHNH 2 , EtOH, cat. AcOH; b) 4M HCl in 1,4-dioxane; c) BrCN, K 2 CO 3 .
  • Step a To a solution of tert-butyl (Z)-3-((dimethylamino)methylene)-4-oxopyrrolidine-1-carboxylate ( Intermediate A , 0.3 g, 1.250 mmol) and (4-methoxyphenyl)hydrazine hydrochloride ( CAS Number 19501-58-7 , available from Spectrochem) (0.66 g, 3.750 mmol) in EtOH (10 ml) was added AcOH (0.1 ml) at rt. The reaction mixture was stirred at rt for 10 min and then heated at 80°C for 4 h.
  • Step b A solution of tert-butyl 1-(4-methoxyphenyl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxylate (0.15 g, 0.474 mmol) in 4M HCl in 1,4-dioxane (5 ml) was stirred at rt for 30 min. The resulting reaction mixture was concentrated under reduced pressure.
  • Step c To a solution of 1-(4-methoxyphenyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole HCl salt (0.075 g, 0.347 mmol) in a mixture of THF:MeOH (10 ml + 1 ml) was added K 2 CO 3 (0.14 g, 1.041 mmol) at rt. The reaction mixture was stirred at rt for 10 min. Cyanogen bromide (0.074 g, 0.694 mmol) was added to the reaction mixture at rt. The reaction mixture was stirred at rt for 1 h.
  • Reagents and conditions a) Conc. HCl, NaNO 2 , SnCl 2 ; b) Ar-NHNH 2 , EtOH, cat. AcOH; c) R 1 R 2 NH, Me 3 Al, DIPEA, THF; d) TFA, DCM; e) BrCN, K 2 CO 3 .
  • Step a A mixture of methyl 3-aminobenzoate ( CAS Number 4518-10-9 , available from Combi Blocks) (8 g, 52.9 mmol) in concentrated HCl (70 ml) was cooled to 0°C. A solution of NaNO 2 (4.38 g, 63.4 mmol) in water (5 ml) was added to the reaction mixture at 0°C and stirred for 30 min. A mixture of SnCl 2 (30 g, 158 mmol) in HCl (30 ml) was added to the reaction mixture at 0°C. The reaction mixture was stirred at a temperature between 0 to 10°C for 2 h.
  • Step b To a solution of tert-butyl (Z)-3-((dimethylamino)methylene)-4-oxopyrrolidine-1-carboxylate (Intermediate A, 6 g, 25 mmol) in EtOH (30 ml) was added methyl 3-hydrazinylbenzoate (4.98 g, 30 mmol) at rt. Glacial AcOH (2 ml) was added to the reaction mixture at rt. The reaction mixture was heated at 80°C for 16 h. The resulting reaction mixture was cooled to rt and poured into saturated aqueous NaHCO 3 solution (80 ml). The obtained mixture was extracted with EtOAc (2 x 50 ml).
  • Step c To a solution of tert-butyl 1-(3-(methoxycarbonyl)phenyl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxylate (0.7 g, 2.04 mmol) in THF (10 ml) was added DIPEA (0.17 ml, 1.02 mmol) at 0°C. Trimethylaluminium (2 M in toluene; 5.10 ml, 10.20 mmol) was added to the reaction mixture at 0°C and stirred for 15 min. Benzylamine (0.27 g, 2.44 mmol) was added to the reaction mixture at 0°C.
  • Step d To a solution of tert-butyl 1-(3-(benzylcarbamoyl)phenyl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxylate (0.15 g, 0.35 mmol) in DCM (5 ml) was added TFA (1.5 ml) at 0°C. The reaction mixture was stirred at rt for 4 h. The resulting reaction mixture was concentrated under reduced pressure to yield N-benzyl-3-(5,6-dihydropyrrolo[3,4-c]pyrazol-1(4H)-yl)benzamide TFA Salt (0.3 g, quantitative). LCMS: Method 1, 1.541 min, MS: ES+ 319.23. This material was used directly for the next step without further purification.
  • Step e To a solution of N-benzyl-3-(5,6-dihydropyrrolo[3,4-c]pyrazol-1(4H)-yl)benzamide TFA Salt (0.3 g, 0.69 mmol) in THF (5 ml) was added K 2 CO 3 (0.52 g, 3.77 mmol) at 0°C. Cyanogen bromide (0.099 g, 0.94 mmol) was added at 0°C. The reaction mixture was stirred for 1 h at rt. The resulting reaction mixture was poured into water (20 ml) and extracted with EtOAc (2 x 5 ml). The combined organic phase was dried over Na 2 SO 4 , filtered and concentrated under reduced pressure.
  • Reagents and conditions a) Conc. HCl, NaNO 2 , SnCl 2 .2H 2 O; b) EtOH, cat. AcOH; c) 4M HCl in 1,4-dioxane; d) BrCN, K 2 CO 3 .
  • Reagents and conditions a) i) BnNHNH 2 , EtOH, cat. AcOH; ii) Boc 2 O, TEA; b) CuBr 2 , isoamylnitrile, MeCN; c) ArB(OH) 2 , Pd(PPh 3 ) 4 , 1,4-dioxane, water; d) polymethylhydroxysilane 20% Pd(OH) 2 /C, EtOH; e) RBr, Cs 2 CO 3 , DMF f) TFA, DCM; g) BrCN, K 2 CO 3 .
  • Step a A solution of tert-butyl 3-cyano-4-oxopyrrolidine-1-carboxylate ( CAS Number 175463-32-8 , available from Combi blocks) (5.0 g, 23.81 mmol) and benzylhydrazine di-hydrochloride ( CAS Number 20570-96-1 , available from Combi blocks) (9.27 g, 47.62 mmol) in EtOH (50 ml) was heated at 70°C for 1 h. The resulting reaction mixture was cooled to rt. (Boc) 2 O (10.39 g, 47.62 mmol) and TEA (7.2 g, 71.43 mmol) were added to the reaction mixture at rt.
  • Step b To a solution of tert-butyl 3-amino-1-benzyl-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxylate (1.0 g, 3.182 mmol) in MeCN (10 ml) was added CuBr 2 (1.06 g, 4.774 mmol) at rt under argon atmosphere. The reaction mixture was stirred at rt for 15 min. Isoamyl nitrite (0.6 g, 4.774 mmol) was added to the reaction mixture at rt. The reaction mixture was stirred at rt for 3 h. The resulting reaction mixture was combined with two other batches prepared on the same scale by an identical method.
  • Step c A solution of tert-butyl 1-benzyl-3-bromo-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxylate (1.5 g, 3.978 mmol) and phenylboronic acid (0.72 g, 5.967 mmol) in 1,4-dioxane:water (8:2) (20ml) was degassed with nitrogen for 30 min at rt. Tetrakis(triphenylphosphine)palladium(0) (0.91 g, 0.795 mmol) and K 2 CO 3 (1.14g, 9.94 mmol) were added to the reaction mixture at rt. The reaction mixture was heated at 90°C for 6 h.
  • Step d To a solution of tert-butyl 1-benzyl-3-phenyl-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxylate (0.5 g, 1.3 mmol) in EtOH (10 ml) was added 20% Pd(OH) 2 (50% moisture) (0.25 g) at rt. Poly(methylhydrosiloxane) (0.5g) was added to the reaction mixture at 0°C and the reaction mixture was stirred at rt for 24 h. The resulting reaction mixture was combined with two batches prepared on the same scale by an identical method. The reaction mixture was filtered through celite pad and washed with EtOH (5 ml).
  • Step e To a solution of tert-butyl 3-phenyl-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxylate (0.5 g, 1.754 mmol) in DMF (5 ml) was added Cs 2 CO 3 (1.14 g, 3.508 mmol) at rt. Methyl iodide (0.33 ml, 5.26 mmol) was added drop wise to the reaction mixture at 0°C. The reaction mixture was stirred at rt for 1 h. The resulting reaction mixture was diluted with water (100 ml) and extracted with EtOAc (2 x 75 ml).
  • Step f To a solution of tert-butyl 1-methyl-3-phenyl-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxylate (0.035 g, 0.120 mmol) in DCM (3 ml) was added TFA (0.35 ml) at rt. The reaction mixture was stirred at rt for 1 h. The resulting reaction mixture was concentrated under reduced pressure.
  • Step g To a solution of 1-methyl-3-phenyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole TFA salt (0.03 g, 0.095 mmol) in THF (3 ml) was added K 2 CO 3 (0.03 g, 0.210 mmol) at rt. Cyanogen bromide (0.01 g, 0.096 mmol) was added to the reaction mixture at rt. The reaction mixture was stirred at rt for 30 min. The resulting reaction mixture was poured into water (30 ml) and extracted with EtOAc (2 x 25 ml). The combined organic phase was dried over Na 2 SO 4 , filtered and concentrated under reduced pressure.
  • Step a To a solution of methyl 5-nitro-1H-pyrazole-3-carboxylate (CAS Number 181585-93-3 , available from Ark Pharma) (0.200 g, 1.168 mmol) in MeOH (10 ml) was added 10% Pd/C (0.020g, 10% w/w) at rt. The reaction mixture was purged with hydrogen gas at rt for 1h. The resulting reaction mixture was carefully filtered through celite hyflow. The celite bed was washed with MeOH (2 x 5ml) and the combined filtrate was concentrated under reduced pressure.
  • Step b To a solution of methyl 5-amino-1H-pyrazole-3-carboxylate (0.150 g, 1.063 mmol) in concentrated HCl (2 ml) was added a solution of NaNO 2 (0.074 g, 1.084 mmol) in water (1.5 ml) at 0°C. The resulting reaction mixture was stirred at 0°C for 30 min. A solution of SnCl 2 (0.403 g, 2.126 mmol) in concentrated HCl (3.3 ml) was added to above resulting mixture at 0°C. The reaction mixture was stirred at rt for 2 h.
  • Step c To a solution of tert-butyl (Z)-3-((dimethylamino)methylene)-4-oxopyrrolidine-1-carboxylate (Intermediate A, 0.200 g, 0.835 mmol) in EtOH (4 ml) was added methyl 5-hydrazinyl-1H-pyrazole-3-carboxylate (0.156 g, 1.000 mmol) at rt. Sodium tert-butoxide (0.170 g, 2.507 mmol) was added to the reaction mixture at rt. The reaction mixture was heated at 80°C for 8 h. The resulting reaction mixture was cooled to rt and concentrated under reduced pressure.
  • Steps d-e These were carried out using a procedure similar to that described for steps d-e of Example 11.
  • Step a To a solution of tert-butyl 3-cyano-4-oxopyrrolidine-1-carboxylate ( CAS Number 175463-32-8 ; 8.00 g, 38.1 mmol) in EtOH (85 ml) was added NH 2 NH 2 .2HCl (4.40 g, 41.9 mmol) at rt. The reaction mixture was heated at 80°C for 30min. The resulting mixture was concentrated under reduced pressure. The residue was poured into saturated NaHCO 3 solution (400 ml) and extracted with EtOAc (3 x 200 ml). The combined organic layer was dried over Na 2 SO 4 , filtered and concentrated under reduced pressure.
  • Step b To a solution of tert-butyl 3-amino-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxylate (2.600 g, 11.607 mmol) in THF (30 ml) was added DIPEA (11.8 ml, 69.6 mmol) at 0°C. Ethyl chloroformate (1.11 ml, 11.72 mmol) was added dropwise to the reaction mixture at 0°C. The reaction mixture was stirred at 0°C for 10 min and then at rt for 2 h. The reaction mixture was poured into water (60 ml) and extracted with EtOAc (3 x 60 ml).
  • Step c To a solution of iodine (3.330 g, 13.120 mmol) in DCM (35 ml) was added isoamyl nitrite (2.95 ml, 21.99 mmol) at rt. 5-Tert-butyl 1-ethyl 3-amino-4,6-dihydropyrrolo[3,4-c]pyrazole-1,5-dicarboxylate (3.200 g, 10.81 mmol) was added to the reaction mixture at rt. The reaction mixture was stirred at rt for 1 h. The resulting reaction mixture was poured into saturated aqueous Na 2 S 2 O 3 solution (150 ml) and extracted with DCM (3 x 150 ml).
  • Step d To a solution of 5-tert-butyl 1-ethyl 3-iodo-4,6-dihydropyrrolo[3,4-c]pyrazole-1,5-dicarboxylate (1.98 g, 4.86 mmol) in MeOH (16 ml) was added TEA (4 ml) at rt. The reaction mixture was stirred at rt for 30 min. The resulting reaction mixture was concentrated under reduced pressure yielding tert-butyl 3-iodo-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxylate (1.630 g, 4.865 mmol). This material was used directly for the next step without further purification.
  • Step e To a solution of tert-butyl 3-iodo-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxylate (1.630 g, 4.865 mmol) in DCM (18 ml) was added DMAP (0.891 g, 7.29 mmol) at 0°C. Boc anhydride (1.27 g, 5.82 mmol) was added to the reaction mixture at 0°C and stirred for 10 min. The reaction mixture was then stirred at rt for 30 min. The resulting reaction mixture was poured into water (100 ml) and extracted with DCM (3 x 50 ml).
  • Step f To a solution of di-tert-butyl 3-iodo-4,6-dihydropyrrolo[3,4-c]pyrazole-1,5-dicarboxylate (0.500 g, 1.147 mmol) in 1,4-dioxane:water (4.5:0.5, 5 ml) prepared in a microwave tube was added phenylboronic acid (0.419 g, 3.434 mmol) at rt. K 2 CO 3 (0.747 g, 3.435 mmol) was added to the reaction mixture at rt. The reaction mixture was degassed for 10-15 min.
  • Tetrakis(triphenylphosphine)palladium(0) (0.132 g, 0.114 mmol) was added to reaction mixture at rt. The tube was sealed and reaction mixture was heated at 100°C for 2 h in a microwave. The resulting mixture was cooled to rt, poured into water (30 ml) and extracted with EtOAc (3 x 30 ml). The combined organic phase was dried over Na 2 SO 4 , filtered and concentrated under reduced pressure.
  • Step g To a solution of di-tert-butyl 3-phenyl-4,6-dihydropyrrolo[3,4-c]pyrazole-1,5-dicarboxylate (0.170 g, 0.44 mmol) in DCM (6 ml) was added TFA (3.5 ml) at 0°C. The reaction mixture was stirred at 0°C for 10 min. The reaction mixture was stirred at rt for 2 h. The resulting reaction mixture was evaporated under reduced pressure.
  • Step h To a solution of 3-phenyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole TFA salt (0.246 g, 0.596 mmol) in THF (5 ml) was added K 2 CO 3 (0.250 g, 1.812 mmol) at 0°C. Cyanogen bromide (0.069 g, 0.651 mmol) was added to the reaction mixture at 0°C. The reaction mixture was stirred at 0°C for 1 h. The resulting reaction mixture was poured into ice cold water (20 ml) and extracted with EtOAc (3 x 20 ml). The combined organic phase was dried over Na 2 SO 4 , filtered and concentrated under reduced pressure.
  • Reagents and conditions a) RNHNH 2 , EtOH; b) ArCl, Ruphos, Pd 2 (dba) 3 , KtBuO, toluene; c) TFA, DCM; d) BrCN, K 2 CO 3 .
  • Step a To a solution of tert-butyl 3-cyano-4-oxopyrrolidine-1-carboxylate ( CAS Number 175463-32-8 available from Combi Blocks) (2.00 g, 9.52 mmol) in EtOH (20 ml) was added methyl hydrazine (0.44 g, 9.52 mmol) at rt. The reaction mixture was heated at 80°C for 10 h. The resulting reaction mixture was cooled to rt and concentrated under reduced pressure.
  • Step b To a solution of tert-butyl 3-amino-2-methyl-2,6-dihydropyrrolo[3,4-c]pyrazole-5(4H)-carboxylate (0.700 g, 2.944 mmol) in toluene (5 ml) was added 3-chloroisoquinoline ( CAS Number 19493-45-9 ; 0.400 g, 2.453 mmol), potassium tert-butoxide (0.549 g, 4.906 mmol) and Ru-Phos (0.114 g, 0.245 mmol) at rt. The reaction mixture was degassed for 15 min before addition of Pd 2 (dba) 3 (0.224 g, 0.245 mmol).
  • Steps c, d The title compound was synthesised from the intermediate above using a procedure similar to that described for steps g and h of Example 29.
  • Step a To a solution of tert-butyl 3-cyano-4-oxopyrrolidine-1-carboxylate ( CAS Number 175463-32-8 ; 0.400 g, 1.904 mmol) in EtOH (5 ml) was added 4-methoxybenzylhydrazine HCl salt ( CAS Number 2011-48-5 ; 0.718 g, 3.805 mmol) at rt. The resulting reaction mixture was heated at 70°C for 1 h. The resulting reaction mixture was cooled to 0°C, neutralized with saturated NaHCO 3 solution (15 ml). The resulting reaction mixture was concentrated under reduced pressure to remove the EtOH.
  • Step b This was carried out using the intermediate above by a procedure similar to that described for Example 30 step b giving tert-butyl 3-(isoquinolin-3-ylamino)-1-(4-methoxybenzyl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxylate
  • Step c A solution of tert-butyl 3-amino-1-(4-methoxybenzyl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxylate (0.200 g, 0.424 mmol) in TFA (2.0 ml) was heated at 70°C for 16 h. The resulting reaction mixture was cooled to rt and concentrated under reduced pressure. The resulting residue was co evaporated with DCM (2 x 5 ml).
  • Step d The title compound was synthesized by using the intermediate mentioned above by a procedure similar to that described for step h of Example 29.
  • LCMS Method 1, 1.946 min, MS: ES+ 277.18; 1 H NMR (400 MHz, DMSO-d6) ⁇ ppm 12.09 - 12.32 (m, 1 H), 9.45 - 9.56 (m, 1 H), 9.00 - 9.05 (m, 1 H), 7.91 - 7.93 (m, 1 H), 7.65 - 7.75 (m, 1 H), 7.44 - 7.57 (m, 2 H), 7.30 - 7.35 (m, 1 H), 4.51 - 4.63 (m, 4 H).
  • Step a This was carried out using 4-carboxamidophenylhydrazine by a procedure similar to that described for step a of Example 31.
  • Step b To a solution of tert-butyl 3-amino-1-(4-carbamoylphenyl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxylate (0.200 g, 0.583 mmol) in DMSO (7 ml) was added NaH (60% dispersion in paraffin oil, 0.070 g, 2.92 mmol) portion wise at 15°C. The resulting reaction mixture was stirred at rt for 30 min. 2-Iodopyridine (0.143 g, 0.70 mmol) was added and the reaction mixture was heated at 130°C for 12 h.
  • Steps c, d These were carried out by a procedure similar to that described for steps c and d of Example 31 to give the title compound.
  • Step a To a solution of 3-phenylpyrazole-5-carboxylic acid (CAS Number 5071-61-4 , 0.2 mmol) in DCM (1 ml) was added HATU (0.2 mmol). The reaction mixture was stirred at 0°C for 20 min. Pyrrolo[3,4-c]pyrazole-5(1H)-carboxylic acid, 3-(aminomethyl)-4,6-dihydro-, 1,1-dimethylethyl ester ( CAS Number 1251002-81-9 , available from Wuxi, 0.2 mmol) and DIPEA (0.6 mmol) were added to the reaction mixture at rt. The reaction mixture was stirred at rt for 16 h. The resulting mixture was concentrated under reduced pressure. The resulting residue was purified by prep-TLC (PE/EtOAc).
  • Step b To a solution of the product of step a in EtOAc (1 ml) was added HCl/EtOAc (4 M, 1 ml). The reaction mixture was stirred at rt for 2h. The resulting mixture was concentrated under reduced pressure. The residue was used for next step directly without further purification.
  • Step c To a solution of the product of step b in EtOH (2 ml) was added cyanogen bromide (0.2 mmol) and NaHCO 3 (0.6 mmol). The reaction mixture was stirred at rt for 16 h. The resulting mixture was concentrated under reduced pressure. The crude was purified by preparative reverse phase HPLC (A: 0.078% CH 3 COONH 4 in water, B: MeCN) to obtain the desired compound. LCMS Method 7, RT 2.283 min, MS: ES+ 334
  • Step a To a solution of tert-butyl 3-(aminomethyl)-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole-5-carboxylate (200 mg, 0.84 mmol) in DMF (4 ml) was added HATU (351 mg, 0.92 mmol), TEA (93 mg, 0.92 mmol, 0.13 ml), then 4-methylbenzoic acid (114 mg, 0.84 mmol) was added, the reaction mixture was stirred at rt for 16 h. The reaction mixture was diluted with water (20 ml) and extracted with EtOAc (20 ml x 2).
  • Step b To a solution of tert-butyl 3-[[(4-methylbenzoyl)-amino]methyl]-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole-5-carboxylate (180 mg, 0.505 mmol), phenylboronic acid (92 mg, 0.757 mmol) in DCM (5 ml) was added Cu(OAc) 2 (138 mg, 0.757 mmol), pyridine (80 mg, 1.01 mmol, 0.08 ml), the reaction mixture was stirred at rt for 16 h under O 2 . The reaction mixture was concentrated under reduced pressure to remove solvent.
  • Step c To a solution of tert-butyl 3-[[(4-methylbenzoyl)amino]methyl]-1-phenyl-4,6-dihydropyrrolo[3,4-c]pyrazole-5-carboxylate (20 mg, 46 ⁇ mol) in EtOAc (1 ml) was added HCl/EtOAc (4 M, 1 ml). The reaction mixture was stirred at rt for 2 h. The resulting mixture was concentrated under reduced pressure. The residue 4-methyl-N-((1-phenyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)methyl)benzamide was used for next step directly without further purification.
  • Step d To a solution of 4-methyl-N-((1-phenyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)methyl)benzamide in EtOH (2 ml) was added cyanogen bromide (0.2 mmol) and NaHCO 3 (0.6 mmol). The reaction mixture was stirred at rt for 16 h. The resulting mixture was concentrated under reduced pressure.
  • Step a To a solution of tert-butyl 3-(acetamidomethyl)-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole-5-carboxylate (500 mg, 1.78 mmol, 1.00 eq) in DCM (3 ml) was added pyridine (66 mg, 0.84 mmol), then acetic anhydride (43 mg, 0.42 mmol) dissolved in DCM (1 ml) was added slowly at 0°C, the reaction mixture was stirred at 0°C for 30 min.
  • Step b To a solution of tert-butyl 3-(acetamidomethyl)-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole-5-carboxylate (500 mg, 1.78 mmol) in DCM (10 ml) was added phenylboronic acid (217 mg, 1.78 mmol), pyridine (282 mg, 3.56 mmol), Cu(OAc) 2 (485 mg, 2.67 mmol), and the reaction mixture was stirred at rt for 16 h. The reaction mixture was concentrated under reduced pressure.
  • Step c To a solution of tert-butyl 3-(acetamidomethyl)-l-phenyl-4,6-dihydropyrrolo[3,4-c]pyrazole-5-carboxylate (80 mg, crude) in EtOAc (1 ml) was added HCl/EtOAc (4 M, 1 ml). The reaction mixture was stirred at rt for 2 h. The resulting mixture was concentrated under reduced pressure. The residue N-((1-phenyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)methyl)acetamide was used for next step directly without further purification.
  • Step d To a solution of N-((1-phenyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)methyl)acetamide in EtOH (2 ml) was added cyanogen bromide (0.2 mmol) and NaHCO 3 (0.6 mmol). The reaction mixture was stirred at rt for 16 h. The resulting mixture was concentrated under reduced pressure.
  • Reagents and conditions a) hydrazine hydrate, AcOH, EtOH, 85°C, 16 h; b) (Boc) 2 O, DCM, THF, rt, 16 h; c) isoamyl nitrite, iodine, rt, 1 h; d) Pd(PPh 3 ) 4 , Cs 2 CO 3 , 1,4-dioxane, water, 100°C, 16 h; e) HCl/ EtOAc, rt, 2 h; f) cyanogen bromide, NaHCO 3 , EtOH, rt, 16 h
  • Step b To a solution of tert-butyl 3-amino-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxylate (267.6 mmol) in DCM (1.6 L) and was added dropwise a solution of (Boc) 2 O (294.3 mmol) in THF (400 ml). The reaction mixture was stirred at rt for 16 h. The reaction mixture was concentrated to provide di-tert-butyl 3-amino-4,6-dihydropyrrolo[3,4-c]pyrazole-1,5-dicarboxylate (231.2 mmol). MS: ES+ 325.0
  • Step c Di-tert-butyl 3-amino-4,6-dihydropyrrolo[3,4-c]pyrazole-1,5-dicarboxylate (92.5 mmol) in DCM (80 ml) was added to a solution of iodine (110.9 mmol) and isoamyl nitrite (184.9 mmol) in DCM (600 ml). The reaction mixture was stirred at rt for 1 h.
  • Step e To a solution of compound 6 in EtOAc (1 ml) was added HCl/EtOAc (4 M, 1 ml). The reaction mixture was stirred at rt for 2 h. The resulting mixture was concentrated under reduced pressure. The residue compound 7 was used for next step directly without further purification.
  • Step f To a solution of compound 7 in EtOH (2 ml) was added cyanogen bromide (0.2 mmol) and NaHCO 3 (0.6 mmol). The reaction mixture was stirred at rt for 16 h. The resulting mixture was concentrated under reduced pressure. The crude was purified by preparative reverse phase HPLC (A: 0.078% CH 3 COONH 4 in water, B: MeCN) to provide compound 8.
  • Reagents and conditions a) Iodine, K 2 CO 3 , DMF; b) ArB(OH) 2 , Pd(PPh 3 ) 4 , Cs 2 CO 3 , 1,4-dioxane/water; c) TFA, DCM; d) BrCN, TEA, THF.
  • Step a A stirred mixture of 4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole-5-carboxylic acid tert-butyl ester (1.00 g, 4.78 mmol), iodine (2.43 g, 9.57 mmol) and K 2 CO 3 (1.32 g, 9.57 mmol) in DMF (15 ml) was heated to 75°C under a nitrogen atmosphere for 18 h. The mixture was cooled to rt, diluted with EtOAc (50 ml) and washed with 10% Na 2 S 2 O 3 (50 ml). The separated aqueous layer was extracted with EtOAc (50 ml), the combined organic extracts were dried over Na 2 SO 4 and evaporated.
  • Step b A mixture of tert-butyl 3-iodo-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxylate (200 mg, 0.60 mmol), 3-fluorobenzeneboronic acid (125 mg, 0.90 mmol) and Cs 2 CO 3 (487 mg, 1.49 mmol) in 1,4-dioxane/water (4:1, 10 ml) was degassed by nitrogen bubbling for 10 min. Tetrakis(triphenylphosphine) palladium(0) (104 mg, 0.09 mmol) was added and degassing continued for 10 min. The stirred mixture was heated at reflux for 18 h, then cooled to rt.
  • Step c TFA (0.5 ml, 6.53 mmol) was added to a stirred suspension of tert-butyl 3-(3-fluorophenyl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxylate (105 mg, 0.35 mmol) in DCM (3 ml). The resulting yellow solution was stirred at rt for 2 h.
  • Step d TEA (0.15 ml, 1.05 mmol) was added to a stirred suspension of 3-(3-fluorophenyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole 2,2,2-trifluoroacetate (128 mg, 0.35 mmol) in THF (5 ml) under a nitrogen atmosphere. Further TEA (0.15 ml, 1.05 mmol) was added to dissolve all solids. The resulting yellow solution was cooled to 0°C and cyanogen bromide (5 M in MeCN, 0.08 ml, 0.42 mmol) was added slowly to give an orange suspension. Stirring was continued at 0°C for 2 h.
  • cyanogen bromide 5 M in MeCN, 0.08 ml, 0.42 mmol
  • Steps a, b Following a similar procedure to Example 57, steps a and b using 2-fluoro-5-methylbenzeneboronic acid ( CAS Number 166328-16-1 ) in step b to give tert-butyl 3-(2-fluoro-5-methylphenyl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxylate.
  • Step c NaH (60% w/w dispersion in oil, 55 mg, 1.36 mmol) was added to a stirred solution of tert-butyl 3-(2-fluoro-5-methylphenyl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxylate (360 mg, 1.14 mmol) in DMF (10 ml) under a nitrogen atmosphere. After 30 minutes, iodomethane (194 mg, 1.36 mmol) was added and the solution stirred at rt for 6 h. Water (10 ml) was added, followed by brine (20 ml), and the mixture was extracted with EtOAc (2 x 50 ml).
  • Steps d, e The title compound was synthesised from tert-butyl 3-(2-fluoro-5-methylphenyl)-1-methyl-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxylate using a procedure similar to that described for Example 57, steps c and d.
  • Step a A solution of N-Boc-3-pyrrolidinone (CAS Number 101385-93-7 ; 5.0 g, 27.0 mmol) in DMF-DMA (32.17 g, 270 mmol) was heated at 100°C for 1.5 h. The resulting mixture was cooled to rt and concentrated under reduced pressure. The obtained residue was triturated with n-pentane (100 ml). The resulting solid was dried under high vacuum yielding tert-butyl 3-((dimethylamino)methylene)-4-oxopyrrolidine-1-carboxylate (4.700 g, 19.58 mmol). LCMS: Method 1, 1.556 min, MS: ES+ 241.43. Step b.
  • Step c To a solution of tert-butyl 1-(3-nitrophenyl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxylate (0.866 g, 2.624 mmol) in MeOH (10 ml) was added 10% dry Pd/C (0.130 g) at rt. The resulting reaction mixture was purged with H 2 for 3 h. The reaction mixture was filtered throw celite pad and washed with EtOH (4 x 10 ml).
  • Step d A solution of tert-butyl 1-(3-aminophenyl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxylate (0.300 g, 1.000 mmol) in DCM (3 ml) was added pyridine (0.396 g, 5.000 mmol) at 0°C. The reaction mixture was stirred at 0°C for 15 min. Cyclopropanesulfonyl chloride ( CAS Number 139631-62-2 , 0.155 g, 1.100 mmol) was added to the reaction mixture at 0°C. The resulting mixture was stirred at rt for 3 h.
  • Step e To a solution of tert-butyl 1-(3-(cyclopropanesulfonamido)phenyl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxylate (0.285 g, 0.705 mmol) in DCM (3 ml) was added TFA (0.402 g, 3.527 mmol) at 0°C. The reaction mixture was stirred at rt for 15 min. The resulting reaction mixture was concentrated under reduced pressure. The obtained residue was co-distilled with DCM (4 x 5 ml).
  • Step a A solution of tert-Butyl 3-cyano-4-oxopyrrolidine-1-carboxylate ( CAS Number 175463-32-8 ; 30.00 g, 142.7 mmol) in EtOH (600 ml) was added AcOH (57 ml, 1000 mmol) and hydrazine hydrate 99% (35 ml, 714 mmol) at rt. The reaction mixture was heated at 85°C for 14 h. The reaction mixture was cooled to rt and concentrated under reduced pressure. The residue was diluted with EtOAc (400 ml) and water (400 ml), pH was adjusted up to ⁇ 8 with by portion wise addition of solid Na 2 CO 3 .
  • Step b To a solution of tert-butyl 3-amino-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxylate (5.000 g, 22.32 mmol) in DCM:THF (4:1, 50 ml) was added (Boc) 2 O (5.352 g, 24.55 mmol) at rt. The resulting reaction mixture was stirred at rt for 18 h. The resulting reaction mixture was combined with one other batch prepared on the same scale by an identical method. The resulting mixture was concentrated under vacuum.
  • Step c To a mixture of iodine (1.880 g, 7.407 mmol) and isoamyl nitrite (1.68 ml, 12.3 mmol) in DCM (10 ml) was added to a solution of di-tert-butyl 3-amino-4,6-dihydropyrrolo[3,4-c]pyrazole-1,5-dicarboxylate (2.000 g, 6.165 mmol) in DCM (40 ml) over 30 min at rt. The reaction mixture was stirred at rt for 14 h. The resulting reaction mixture was poured into saturated Na 2 S 2 O 3 solution (20 ml) and extracted with DCM (2 x 20 ml).
  • Step d A mixture of di-tert-butyl 3-iodo-4,6-dihydropyrrolo[3,4-c]pyrazole-1,5-dicarboxylate (0.400 g, 0.918 mmol), 2-fluoro-4-(methoxycarbonyl)phenylboronic acid ( CAS Number 603122-84-5 ; 0.218 g, 1.102 mmol) and NaHCO 3 (0.154 g, 1.837 mmol) in DMF:water (9:1) (8 ml) was degassed with nitrogen for 10 min at rt before addition of PdCl 2 (dppf) DCM complex (0.91 g, 0.795 mmol). The reaction mixture was heated at 100°C for 4 h.
  • Step e To a solution of tert-butyl 3-(2-fluoro-4-(methoxycarbonyl)phenyl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxylate (0.180 g, 0.498 mmol) in MeOH (5 ml) was added LiOH.H 2 O (0.837, 1.994 mmol) at rt. The reaction mixture was heated at 85°C for 12 h. The reaction mixture cooled to rt and concentrated under vacuum. The obtained crude was diluted with water (10 ml) and extracted with EtOAc (2 x 10 ml).
  • Step f To a solution of 4-(5-(tert-butoxycarbonyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)-3-fluorobenzoic acid (0.145 g, 0.417 mmol) in DMF (5 ml) were added HATU (0.476 g, 1.253 mmol) and DIPEA (0.215 ml, 1.253 mmol) at 0°C. The reaction mixture was stirred at 0°C for 30 min before addition of benzylamine (0.053 g, 0.501 mmol). The resulting reaction mixture was stirred at rt for 12 h.
  • the USP7 construct was PCR amplified and cloned into a pFLAG-CMV-6a vector (Sigma-Aldrich) with an N-terminal FLAG tag.
  • HEK293T cells were transfected with FLAG-USP7 using TransIT-LT1 transfection reagent (Mirus) according to the manufacturer's instructions. Cells were harvested 40 hours after transfection.
  • lysis buffer 50 mM Tris, pH 7.5, 150 mM NaCl, 3 mM EDTA, 0.5% NP40, 10% glycerol, 5 mM beta-mercaptoethanol, protease inhibitors (complete mini, Roche) and phosphatase inhibitors (PhosSTOP mini, Roche). Lysates were incubated for 30 min on ice and centrifuged at 4000 rpm for 10 min at 4° C.
  • Soluble supernatant was added to FLAG affinity resin (EZview Rad ANTI-FLAG M2 affinity gel, Sigma-Aldrich) equilibrated in low salt buffer (20 mM Tris, pH 7.5, 150 mM NaCl, 0.5 mM EDTA, 5 mM beta-mercaptoethanol) and incubated at 4° C for 3 hours rotating. The resin was spun at 2000 rpm for 2 min and the supernatant was removed.
  • FLAG affinity resin EZview Rad ANTI-FLAG M2 affinity gel, Sigma-Aldrich
  • the resin was washed two times with low salt buffer plus protease inhibitors (complete mini, Roche) and phosphatase inhibitors (PhosSTOP mini, Roche) and one time with high salt buffer (20 mM Tris, pH 7.5, 500 mM NaCl, 0.5 mM EDTA, 5 mM beta-mercaptoethanol, protease inhibitors (complete mini, Roche) and phosphatase inhibitors (PhosSTOP mini, Roche).
  • elution buffer (10 mM Tris, pH 7.5, 150 mM NaCl, 0.5 mM EDTA, 10% glycerol, 0.5% NP40, 5 mM beta-mercaptoethanol, 0.15 mg/ml 3X FLAG peptide (Sigma-Aldrich)
  • elution buffer 10 mM Tris, pH 7.5, 150 mM NaCl, 0.5 mM EDTA, 10% glycerol, 0.5% NP40, 5 mM beta-mercaptoethanol, 0.15 mg/ml 3X FLAG peptide (Sigma-Aldrich)
  • Reactions were performed in duplicate in black 384 well plates (small volume, Greiner 784076) in a final reaction volume of 21 ⁇ l.
  • USP7 was diluted in reaction buffer (20 mM Tris, pH 7.5, 100 mM NaCl, 0.05% Tween 20, 0.5 mg/ml BSA, 5 mM - beta mercaptoethanol) to the equivalent of 0, 0.0005, 0.001, 0.0025, and 0.005 ⁇ l/well.
  • Buffer was optimised for optimal temperature, pH, reducing agent, salts, time of incubation, and detergent.
  • Reactions were initiated by the addition of 50 nM of TAMRA labelled peptide linked to ubiquitin via an iso-peptide bond as fluorescence polarisation substrate. Reactions were incubated at room temperature and read every 2 min for 120 min. Readings were performed on a Pherastar Plus (BMG Labtech). ⁇ Excitation 540 nm; ⁇ Emission 590 nm.
  • Dilution plates were prepared at 21 times the final concentration (2100 ⁇ M for a final concentration of 100 ⁇ M) in 50% DMSO in a 96-well polypropylene V-bottom plate (Greiner #651201). A typical 8-point dilution series would be 100, 30, 10, 3, 1, 0.3, 0.1, 0.03 ⁇ M final. Reactions were performed in duplicate in black 384 well plates (small volume, Greiner 784076) in a final reaction volume of 21 ⁇ l. Either 1 ⁇ l of 50% DMSO or diluted compound was added to the plate.
  • USP7 was diluted in reaction buffer (20 mM Tris, pH 7.5, 100 mM NaCl, 0.05% Tween 20, 0.5 mg/ml BSA, 5 mM - beta mercaptoethanol) to the equivalent of 0.0025 ⁇ l/well and 10 ⁇ l of diluted USP7 was added to the compound. Enzyme and compound were incubated for 30 min at room temp. Reactions were initiated by the addition of 50 nM of TAMRA labelled peptide linked to ubiquitin via an iso-peptide bond as fluorescence polarisation substrate. Reactions were read immediately after addition of substrate and following a 2 hr incubation at room temperature. Readings were performed on a Pherastar Plus (BMG Labtech). ⁇ Excitation 540 nm; ⁇ Emission 590 nm.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Claims (16)

  1. Composé de formule I :
    Figure imgb0117
     tautomère de celui-ci, ou sel pharmaceutiquement acceptable dudit composé ou tautomère, dans lequel
    R1a, R1b, R1c et R1d sont chacun indépendamment hydrogène ou alkyle en C1-C6 éventuellement substitué, ou R1a et R1b forment ensemble un cycle cycloalkyle en C3-C6, ou R1c et R1d forment ensemble un cycle cycloalkyle en C3-C6 ;
    A est un cycle aromatique azoté à 5 chaînons, qui est substitué par -Q1-B et (-Q2-(D)m)n ;
    m représente 0 ou 1 ;
    n représente 0, 1 ou 2 ;
    Q1 est une liaison covalente, un atome d'oxygène, un atome de soufre, -OR4-, -SO-, -SO2-, -C(O)-, - C(O)O-, alkylène C0-C3-alkylène-C(O)NR2-C0-C3, alkylène C0-C3-alkylène-NR2-C0-C3, alkylène C0-C3-alkylène-NR2C(O)-C0-C3, -NR2C(O)NR3-, -SO2NR2-, NR2SO2-, -NR2SO2NR3-, -NR2C(O)O-, - NR2C(O)OR4-, alkylène en C1-C6 éventuellement substitué, ou alcénylène en C2-C6 éventuellement substitué ;
    R2 et R3 sont chacun indépendamment hydrogène ou alkyle en C1-C6 éventuellement substitué ;
    R4 est un alkylène en C1-C6 éventuellement substitué ;
    B est un cycle aryle ou hétéroaryle, monocyclique ou bicyclique, de 5 à 10 chaînons ;
    dans laquelle B est non substitué ou substitué par un à quatre substituants, chacun indépendamment choisi parmi halogène, cyano, oxo, hydroxyl, -SR11, alkyle en -C1-C6 éventuellement substitué, alcoxy en -C1-C6 éventuellement substitué, alcényle en -C2-C6 éventuellement substitué, alcynyle en -C2-C6 éventuellement substitué, -Q3a-R13, -Q3a-O-Q3b-R13, -Q3a-S-Q3b-R13, -Q3a-SO-Q3b-R13, -Q3a-NR11CONR12R12a, -Q3a-NR11CONR12-Q3a-R13, -Q3a-NR11R12, -Q3a-NR11-Q3b-R13, -Q3a-COR11, -Q3a-CO-Q3b-R13, -Q3a-NR11COR12, -Q3a-NR11CO-Q3b-R13, -Q3a-NR11C(O)OR12, -Q3a-SO2R11, -Q3a-SO2-Q3b-R13, Q3a-CONR11R12, -Q3a-CONR11-Q3b-R13, -Q3a-CO2R11, -Q3a-CO2-Q3b-R13, -Q3a-SO2NR11R12, - Q3a-SO2NR11-Q3b-R13, -Q3a-NR11SO2R12, -Q3a-NR11SO2-Q3b-R13, -Q3a-NR11SO2NR12R12a, and -Q3a-NR11SO2NR12-Q3b-R13;
    Q3a et Q3b sont chacun indépendamment une liaison covalente, alkylène en C1-C6 éventuellement substitué, ou alcénylène en C2-C6 éventuellement substitué ;
    R11, R12 et R12a sont chacun indépendamment hydrogène ou alkyle en C1-C6 éventuellement substitué ;
    R13 représente un cycle hétérocyclyle, hétéroaryle, aryle ou cycloalkyle de 3 à 10 chaînons ;
    dans laquelle R13 est non substitué ou substitué par un à quatre substituants, choisis chacun indépendamment parmi halogène, hydroxyle, thiol, cyano, amino, amido, nitro, SF5, alkyle en C1-C3, et alcoxy en C1-C3 ;
    chaque Q2 est indépendamment halogène, cyano, nitro, OR5, -SR5, -NR5R6, -CONR5R6, -C0-C3-alkylène-NR5COR6-, -NR5CONR6R6a, -COR5, -C(O)OR5, -SO2R5, -SO2NR5R6, -NR5SO2R6, - NR5SO2NR6R6a, -NR5C(O)OR6, alkyle en -C1-C6 éventuellement substitué, alcényle en -C2-C6 éventuellement substitué, une liaison covalente, un atome d'oxygène, un atome de soufre, -OR7-, -SO-, -SO2-, -CO-, -C(O)O-, alkylène C0-C3-alkylène-C(O)NR5-C0-C3, alkylène C0-C3-alkylène-NR5-C0-C3, alkylène C0-C3-alkylène-NR5C(O)-C0-C3, -NR5CONR6-, -SO2NR5-, NR5SO2-, -NR5SO2NR6-, - NR5C(O)O-, -NR5C(O)OR7-, alkylène en C1-C6 éventuellement substitué, ou alkylène en -C2-C6 ;
    R5, R6 et R6a sont chacun indépendamment hydrogène ou alkyle en C1-C6 éventuellement substitué ;
    R7 est un alkylène en C1-C6 éventuellement substitué ;
    chaque D est indépendamment un cycle hétérocyclyle, hétéroaryle, cycloalkyle ou aryle, monocyclique ou bicyclique, de 3 à 10 chaînons ;
    dans laquelle D est non substitué ou substitué par un à quatre substituants, chacun indépendamment choisi parmi un alkyle en C1-C6, un alcoxy en C1-C6, et -CONR14R15 ;
    R14 et R15 sont chacun indépendamment hydrogène ou alkyle en C1-C6 éventuellement substitué ; et
    dans laquelle les éventuels substituants des groupes alkyle, alcoxy, alcényle, alcynyle, alkylène et alcénylène, sont choisis parmi halogène, hydroxyle et cyano.
  2. Composé selon la revendication 1, présentant la formule II :
    Figure imgb0118
     ou sel pharmaceutiquement acceptable de celui-ci, dans lequel
    ------- représente une liaison aromatique ;
    p représente 0 ou 1 ;
    q représente 0 ou 1 ;
    dans laquelle p et q ne sont pas tous les deux 0 et un de p et q vaut 1 ;
    R8 est un hydrogène, -Q1-B ou -Q2-(D)m ;
    R9 est un hydrogène ou alkyle en C1-C6 éventuellement substitué ;
    R10 est un hydrogène, -Q1-B ou -Q2-(D)m ;
    dans laquelle R8 ou R10 est -Q1-B ; et
    R1a , R1b, R1c, R1d, m, Q1, Q2, B et D sont tels que définis dans la revendication 1.
  3. Composé selon la revendication 2, dans lequel R8 est -Q1-B ; et R10 est un hydrogène ou -Q2-(D)m.
  4. Composé selon la revendication 2, dans lequel R8 est hydrogène ou -Q2-(D)m ; et R10 est -Q1-B.
  5. Composé selon l'une quelconque des revendications 1 à 4, dans lequel Q1 est choisi parmi une liaison covalente, CH2NHC(O), NH, CH2, ou CH2NHC(O)CH2.
  6. Composé selon l'une quelconque des revendications 1 à 5, dans lequel B est choisi parmi phényle, quinolinyle, pyridinyle, pyrazolyle, indazolyle, imidazolyle, isoquinolinyle et imidazopyridinyle éventuellement substitué.
  7. Composé selon l'une quelconque des revendications 1 à 6, dans lequel B est substitué par un à quatre substituants choisis parmi fluor, chlore, cyano, méthyle, propyle, CF3, méthoxy, propoxy, OCF3, C(O)NH2, C(O)NHCH3, C(O)N(CH3)2, SO2N(CH3)2, R13, CH2R13, C(O)NHR13, C(O)NHCH2R13, NHC(O)-(C2 alkylène)-R13, C(O)NH-éthylène-R13, OCH2R13, OR13, C(O)R13, SO2NH, et NHSO2R13 ; dans lequel R13 est choisi parmi phényle, pyridinyle, pipérazinyle et cyclopropyle.
  8. Composé selon l'une quelconque des revendications 1 à 7, dans lequel chaque occurrence de Q2 est indépendamment choisie parmi une liaison covalente, méthyle, isopropyle, NHC(O)CH3, CH2, NH ou CH2NR5C(O).
  9. Composé selon l'une quelconque des revendications 1 à 8, dans lequel D est choisi parmi phényle, isoquinolinyle et pyridinyle.
  10. Composé selon l'une quelconque des revendications 1 à 9, dans lequel R1a, R1b, R1c et R1d représentent chacun un hydrogène.
  11. Composé de formule I selon la revendication 1, choisi dans le groupe constitué de :
    1-(4-méthoxyphényl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carbonitrile ;
    1-phényl-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carbonitrile ;
    1-(4-fluorophényl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carbonitrile ;
    1-(2-fluorophényl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carbonitrile ;
    4-(5-cyano-5,6-dihydropyrrolo[3,4-c]pyrazol-1(4H)-yl)benzamide ;
    1-(quinolin-3-yl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carbonitrile ;
    1-(3-méthoxyphényl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carbonitrile ;
    1-(1-phényl-1H-pyrazol-4-yl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carbonitrile ;
    1-(1-phényl-1H-imidazol-4-yl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carbonitrile ;
    3-méthyl-1-phényl-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carbonitrile ;
    N-benzyl-3-(5-cyano-5,6-dihydropyrrolo[3,4-c]pyrazol-1(4H)-yl)benzamide ;
    3-(5-cyano-5,6-dihydropyrrolo[3,4-c]pyrazol-1(4H)-yl)-N-(1-phényléthyl)benzamide ;
    3 -(5 -cyano-5,6-dihydropyrrolo[3,4-c]pyrazol-1(4H)-yl)-N-(pyridin-2-ylméthyl)benzamide ;
    4-(5-cyano-5,6-dihydropyrrolo[3,4-c]pyrazol-1(4H)-yl)-N-(pyridin-2-ylméthyl)benzamide ;
    4-(5-cyano-5,6-dihydropyrrolo[3,4-c]pyrazol-l(4H)-yl)-N-méthylbenzamide ;
    4-(5-cyano-3-méthyl-5,6-dihydropyrrolo[3,4-c]pyrazol-1(4H)-yl)benzamide ;
    1-(1-méthyl-1H-indazol-5-yl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carbonitrile ;
    5-(5-cyano-5,6-dihydropyrrolo[3,4-c]pyrazol-1(4H)-yl)-2-méthoxy-N-méthylbenzamide ;
    1-(1H-indazol-3-yl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carbonitrile ;
    1-(3-phényl-1H-pyrazol-5-yl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carbonitrile ;
    1-méthyl-3-phényl-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carbonitrile ;
    2-méthyl-3-phényl-2,6-dihydropyrrolo[3,4-c]pyrazole-5(4H)-carbonitrile ;
    1-isopropyl-3-phényl-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carbonitrile ;
    1-benzyl-3-phényl-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carbonitrile ;
    1-benzyl-3-(5-isopropyl-2-méthoxyphényl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carbonitrile ;
    3-(5-isopropyl-2-méthoxyphényl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carbonitrile ;
    3-(2-fluoro-5-méthylphényl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carbonitrile ;
    5-(5-cyano-5,6-dihydropyrrolo[3,4-c]pyrazol-1(4H)-yl)-1H-pyrazole-3-carboxamide ;
    3 -phényl-4,6-dihydropyrrolo [3,4-c]pyrazole-5 (1H)-carbonitrile ;
    3-(isoquinolin-3-ylamino)-2-méthyl-2,6-dihydropyrrolo[3,4-c]pyrazole-5(4H)-carbonitrile ;
    3-(isoquinolin-3-ylamino)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carbonitrile ;
    1-benzyl-3-(isoquinolin-3-ylamino)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carbonitrile ;
    4-(5 -cyano-3 -(pyridin-2-ylamino)-5,6-dihydropyrrolo[3,4-c]pyrazol-1(4H)-yl)benzamide ;
    N-((5-cyano-1,4,5,6-tétrahydropyrrolo[3,4-c]pyrazol-3-yl)méthyl)-3-phényl-1H-pyrazole-5-carboxamide ;
    N-((5-cyano-1-phényl-1,4,5,6-tétrahydropyrrolo[3,4-c]pyrazol-3-yl)méthyl)-4-méthylbenzamide ;
    N-((5-cyano-1-phényl-1,4,5,6-tétrahydropyrrolo[3,4-c]pyrazol-3-yl)méthyl)acétamide ;
    3-(4-(benzyloxy)phényl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carbonitrile ;
    3-(3-cyanophényl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carbonitrile ;
    3-(1-méthyl-1H-pyrazol-5-yl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carbonitrile ;
    3-(3-(trifluorométhoxy)phényl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carbonitrile ;
    3-(4-phénoxyphényl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carbonitrile ;
    3-(4-cyanophényl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carbonitrile ;
    3-(2-fluoro-4-(trifluorométhyl)phényl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carbonitrile ;
    3-(2-chloro-5-(trifluorométhoxy)phényl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carbonitrile ;
    5-(5-cyano-1,4,5,6-tétrahydropyrrolo[3,4-c]pyrazol-3-yl)-N-méthylpicolinamide ;
    3-(6-méthoxypyridin-3-yl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carbonitrile ;
    3-(5-cyano-1,4,5,6-tétrahydropyrrolo[3,4-c]pyrazol-3-yl)-N,N-diméthylbenzènesulfonamide ;
    3-(5-fluoro-2-isopropoxyphényl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carbonitrile ;
    N-benzyl-4-(5-cyano-1,4,5,6-tétrahydropyrrolo[3,4-c]pyrazol-3-yl)benzamide ;
    3-(6-isopropoxypyridin-3-yl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carbonitrile ;
    3-(4-(4-méthylpipérazine-1-carbonyl)phényl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carbonitrile ;
    3-(1-méthyl-1H-indazol-5-yl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carbonitrile ;
    3-(1-benzyl-1H-pyrazol-5-yl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carbonitrile ;
    3-(5-methyl-1H-indazol-4-yl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carbonitrile ;
    3-(5-cyano-1,4,5,6-tétrahydropyrrolo[3,4-c]pyrazol-3-yl)-N-cyclopropylbenzènesulfonamide ;
    N-(3-(5-cyano-1,4,5,6-tétrahydropyrrolo[3,4-c]pyrazol-3-yl)phényl)cyclopropanesulfonamide ;
    3-(3-fluorophényl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carbonitrile;
    3-(2-fluorophényl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carbonitrile ;
    3-(4-fluorophényl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carbonitrile ;
    3-(2-fluoro-5-méthylphényl)-1-méthyl-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carbonitrile;
    3-(2-fluoro-5-méthylphényl)-2-méthyl-2,6-dihydropyrrolo[3,4-c]pyrazole-5(4H)-carbonitrile ;
    3-(5-isopropyl-2-méthoxyphényl)-1-méthyl-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carbonitrile ;
    3-(5-isopropyl-2-méthoxyphényl)-2-méthyl-2,6-dihydropyrrolo[3,4-c]pyrazole-5(4H)-carbonitrile ;
    3-(5-éthyl-2-méthoxyphényl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carbonitrile ;
    6-chloro-N-((5-cyano-1,4,5,6-tétrahydropyrrolo[3,4-c]pyrazol-3-yl)méthyl)imidazo[1,2-a]pyridine-2-carboxamide ;
    3-(4-(4-méthylpipérazin-1-yl)phényl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carbonitrile ;
    3-(4-chloro-2-méthoxyphényl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(4H)-carbonitrile ;
    3-(1-(1-méthylpipéridin-4-yl)-1H-pyrazol-4-yl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carbonitrile ;
    3-(6-(4-méthylpipérazin-1-yl)pyridin-3-yl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carbonitrile ;
    3-(2-méthoxy-4-(1H-pyrazol-1-yl)phényl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(4H)-carbonitrile ;
    3 -(3 -(4-méthylpipérazin-1-yl)phényl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carbonitrile;
    3-(4-morpholinophényl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carbonitrile ;
    3-(2-fluoro-4-(4-méthylpipérazin-1-yl)phényl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carbonitrile ;
    3-(3-méthyl-4-(4-méthylpipérazin-1-yl)phényl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carbonitrile ;
    3 -(3 -(2-oxooxazolidin-3 -yl)phényl)-4,6-dihydropyrrolo [3,4-c]pyrazole-5(1H)-carbonitrile ;
    3 -(3 -(2-oxopyrrolidin-1-yl)phényl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carbonitrile;
    3-(5-chloro-2-méthoxyphényl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(4H)-carbonitrile ;
    N-(3-(5-cyano-5,6-dihydropyrrolo[3,4-c]pyrazol-1(4H)-yl)phényl)cyclopropanesulfonamide ; et
    N-benzyl-4-(5-cyano-1,4,5,6-tétrahydropyrrolo[3,4-c]pyrazol-3-yl)-3-fluorobenzamide ;
    tautomère de celui-ci, ou sel pharmaceutiquement acceptable dudit composé ou dudit tautomère.
  12. Composé selon l'une quelconque des revendications 1 à 11, destiné à être utilisé en tant que médicament.
  13. Composé selon l'une quelconque des revendications 1 à 11, destiné à être utilisé dans le traitement du cancer.
  14. Composé pour une utilisation selon la revendication 13, dans lequel le cancer est choisi parmi les cancers du sein, de l'ovaire, de la prostate, du poumon, du rein, de l'estomac, du côlon, des testicules, de la tête et du cou, du pancréas, du cerveau, de la peau, des os, du foie, des tissus mous, les cancers des organes tissulaires, les cancers des cellules sanguines, LMC, LAM, un lymphome du manteau, un neuroblastome, un mélanome, un sarcome des tissus mous, un liposarcome, un sarcome fibroblastique, un léiomyosarcome, un carcinome hépatocellulaire, un ostéosarcome, un cancer de l'œsophage, une leucémie, un lymphome, un myélome de couleur et un carcinome pulmonaire non à petites cellules.
  15. Composé selon l'une quelconque des revendications 1 à 11, destiné à être utilisé dans le traitement d'une maladie impliquant un dysfonctionnement mitochondrial choisie parmi un trouble du SNC ; une maladie neurodégénérative ; la maladie de Parkinson ; la maladie d'Alzheimer ; une sclérose latérale amyotrophique ; la maladie de Huntington ; une angine de poitrine ; un accident vasculaire cérébral ; une démence à corps de Lewy ; une démence fronto-temporale ; une sclérose en plaques ; une myopathie mitochondriale ; l'encéphalopathie ; l'acidose lactique ; le syndrome d'épisodes vasculaires cérébraux ; la neuropathie optique héréditaire de Leber ; le cancer ; la neuropathie, l'ataxie, la rétinite pigmentaire, le syndrome de Leigh hérité de la mère ; la maladie de Danon ; le diabète ; la néphropathie diabétique ; les troubles métaboliques ; l'insuffisance cardiaque ; la cardiopathie ischémique menant à un infarctus du myocarde ; les maladies psychiatriques, la schizophrénie ; le déficit multiple en sulfatases ; la mucolipidose type II ; la mucolipidose type III ; la mucolipidose type IV ; la gangliosidose à GM1 ; la céroïde-lipofuscinose neuronale ; la maladie d'Alpers ; le syndrome de Barth ; les anomalies de la bêta-oxydation ; le déficit en carnitine-acyl-carnitine ; le déficit en carnitine ; les syndromes de déficit en créatine ; le déficit en coenzyme Q10 ; le déficit en complexe I ; le déficit en complexe II ; le déficit en complexe III ; le déficit en complexe IV ; le déficit en complexe V ; le déficit en COX ; le syndrome d'ophtalmoplégie externe progressive chronique ; le déficit en CPT I ; le déficit en CPT II ; l'acidurie glutarique type II ; le syndrome de Kearns-Sayre ; l'acidose lactique ; le déficit en acyl-CoA déshydrogénase à longue chaîne ; la maladie ou le syndrome de Leigh ; la cardiomyopathie infantile mortelle ; la maladie de Luft ; l'acidurie glutarique type II ; le déficit en acyl-CoA déshydrogénase à chaîne moyenne ; le syndrome MERRF (épilepsie myoclonique associée à des fibres rouges déchiquetées) ; la cytopathie mitochondriale ; le syndrome de l'ataxie récessive mitochondriale ; le syndrome de déplétion de l'ADN mitochondrial ; l'encéphalopathie myo-neuro-gastrointestinale ; le syndrome de Pearson ; le déficit en pyruvate déshydrogénase ; le déficit en pyruvate carboxylase ; les mutations de POLG ; le déficit en 3-hydroxyacyl-CoA déshydrogénase à chaîne moyenne/courte ; et le déficit en acyl-CoA déshydrogénase à très longue chaîne.
  16. Composition pharmaceutique comprenant un composé selon l'une quelconque des revendications 1 à 11, tautomère de celui-ci, ou sel pharmaceutiquement acceptable dudit composé ou dudit tautomère, conjointement avec au moins un excipient pharmaceutiquement acceptable.
EP17713402.0A 2016-03-18 2017-03-17 Dérivés de 4,6-dihydropyrrolo[3,4-c]pyrazole-5(1h)-carbonitrile pour le traitement du cancer Active EP3430012B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1604638.5A GB201604638D0 (en) 2016-03-18 2016-03-18 Novel compounds
PCT/GB2017/050755 WO2017158381A1 (fr) 2016-03-18 2017-03-17 Dérivés de 4,6-dihydropyrrolo[3,4-c]pyrazole-5(1h)-carbonitrile pour le traitement du cancer

Publications (2)

Publication Number Publication Date
EP3430012A1 EP3430012A1 (fr) 2019-01-23
EP3430012B1 true EP3430012B1 (fr) 2021-06-16

Family

ID=55968542

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17713402.0A Active EP3430012B1 (fr) 2016-03-18 2017-03-17 Dérivés de 4,6-dihydropyrrolo[3,4-c]pyrazole-5(1h)-carbonitrile pour le traitement du cancer

Country Status (7)

Country Link
US (1) US11306096B2 (fr)
EP (1) EP3430012B1 (fr)
JP (1) JP6959248B2 (fr)
CN (1) CN108473502B (fr)
GB (1) GB201604638D0 (fr)
MA (1) MA43745A (fr)
WO (1) WO2017158381A1 (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ736450A (en) 2015-03-30 2022-04-29 Mission Therapeutics Ltd 1-cyano-pyrrolidine compounds as usp30 inhibitors
US10669234B2 (en) 2015-07-14 2020-06-02 Mission Therapeutics Limited Cyanopyrrolidines as dub inhibitors for the treatment of cancer
GB201521109D0 (en) 2015-11-30 2016-01-13 Mission Therapeutics Ltd Novel compounds
GB201522267D0 (en) 2015-12-17 2016-02-03 Mission Therapeutics Ltd Novel compounds
GB201522768D0 (en) 2015-12-23 2016-02-03 Mission Therapeutics Ltd Novel compounds
GB201602854D0 (en) 2016-02-18 2016-04-06 Mission Therapeutics Ltd Novel compounds
GB201603779D0 (en) 2016-03-04 2016-04-20 Mission Therapeutics Ltd Novel compounds
GB201604647D0 (en) 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
US11352339B2 (en) 2016-03-24 2022-06-07 Mission Therapeutics Limited 1-cyano-pyrrolidine derivatives as DUB inhibitors
JP6959332B2 (ja) 2016-09-27 2021-11-02 ミッション セラピューティクス リミティド Ｕｓｐ３０の阻害剤としての活性を有するシアノピロリジン誘導体
GB201616511D0 (en) 2016-09-29 2016-11-16 Mission Therapeutics Limited Novel compounds
GB201616627D0 (en) * 2016-09-30 2016-11-16 Mission Therapeutics Limited Novel compounds
TWI771327B (zh) 2016-10-05 2022-07-21 英商使命醫療公司 新穎化合物
GB201617758D0 (en) 2016-10-20 2016-12-07 Almac Discovery Limited Pharmaceutical compounds
GB201708652D0 (en) 2017-05-31 2017-07-12 Mission Therapeutics Ltd Novel compounds and uses
US11059809B2 (en) 2017-06-20 2021-07-13 Mission Therapeutics Limited Substituted cyanopyrrolidines with activity as DUB inhibitors
EA202090871A1 (ru) 2017-10-06 2020-07-03 Форма Терапьютикс, Инк. Ингибирование убиквитин-специфической пептидазы 30
SG11202010068VA (en) 2018-04-25 2020-11-27 Bayer Ag Novel heteroaryl-triazole and heteroaryl-tetrazole compounds as pesticides
US11572374B2 (en) 2018-08-14 2023-02-07 Amgen Inc. N-cyano-7-azanorbornane derivatives and uses thereof
EP4218934A1 (fr) 2018-10-05 2023-08-02 Forma Therapeutics, Inc. Inhibition de la protéase 30 spécifique de l'ubiquitine (usp30)
CN113453679A (zh) 2018-12-20 2021-09-28 C4医药公司 靶向蛋白降解
GB201905375D0 (en) 2019-04-16 2019-05-29 Mission Therapeutics Ltd Novel compounds
GB201905371D0 (en) 2019-04-16 2019-05-29 Mission Therapeutics Ltd Novel compounds
GB201912674D0 (en) 2019-09-04 2019-10-16 Mission Therapeutics Ltd Novel compounds
CR20220316A (es) 2019-12-06 2022-10-07 Vertex Pharma Tetrahidrofuranos sustituidos como moduladores de canales de sodio
JP2023512038A (ja) * 2020-01-29 2023-03-23 フォグホーン セラピューティクス インコーポレイテッド 化合物及びその使用
GB202001980D0 (en) 2020-02-13 2020-04-01 Almac Discovery Ltd Therapeutic mentods
BR112022020058A2 (pt) 2020-04-08 2022-11-22 Mission Therapeutics Ltd N-cianopirrolidinas com atividade como inibidores de usp30
US20230219939A1 (en) 2020-05-28 2023-07-13 Mission Therapeutics Limited N-(1-cyano-pyrrolidin-3-yl)-5-(3-(trifluoromethyl)phenyl)oxazole-2-carboxamide derivatives and the corresponding oxadiazole derivatives as usp30 inhibitors for the treatment of mitochondrial dysfunction
IL298710A (en) 2020-06-04 2023-02-01 Mission Therapeutics Ltd N-cyanopyrrolidines with activity as USP30 inhibitors
JP2023528087A (ja) 2020-06-08 2023-07-03 ミッション セラピューティクス リミティド ミトコンドリア機能不全、癌、及び線維症の治療に使用されるＵＳＰ３０阻害剤としての１－（５－（２－シアノピリジン－４－イル）オキサゾール－２－カルボニル）－４－メチルヘキサヒドロピロロ［３，４－ｂ］ピロール－５（１Ｈ）－カルボニトリル
GB202016800D0 (en) 2020-10-22 2020-12-09 Mission Therapeutics Ltd Novel compounds
AR126073A1 (es) 2021-06-04 2023-09-06 Vertex Pharma N-(hidroxialquil(hetero)aril)tetrahidrofuran carboxamidas como moduladores de canales de sodio
WO2023099561A1 (fr) 2021-12-01 2023-06-08 Mission Therapeutics Limited N-cyanopyrrolidines substituées ayant une activité en tant qu'inhibiteurs de l'usp30
GB202200753D0 (en) 2022-01-21 2022-03-09 Almac Discovery Ltd Pharmaceutical compounds

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6835727B2 (en) 2000-04-06 2004-12-28 Merck Frosst Canada & Co. Cathepsin cysteine protease inhibitors
US20130156731A1 (en) 2009-12-22 2013-06-20 Kevin X. Chen Fused tricyclic compounds and methods of use thereof for the treatment of viral diseas
US8809377B2 (en) * 2010-09-24 2014-08-19 The Regents Of The University Of Michigan Deubiquitinase inhibitors and methods for use of the same
WO2012174199A1 (fr) 2011-06-16 2012-12-20 Merck Sharp & Dohme Corp. Dérivés d'imidazopyridin-2-one
EP2565186A1 (fr) 2011-09-02 2013-03-06 Hybrigenics S.A. Inhibiteurs sélectifs et réversibles de la protéase 7 spécifique de l'ubiquitine
WO2013044865A1 (fr) * 2011-09-30 2013-04-04 山东轩竹医药科技有限公司 Antibiotiques oxazolidinones contenant un cycle fusionné
EP2938610A2 (fr) * 2012-12-28 2015-11-04 The U.S.A. as represented by the Secretary, Department of Health and Human Services Inhibiteurs du complexe usp1/uaf1 désubiquitinase et leurs utilisations
SG11201608242XA (en) 2014-04-04 2016-10-28 Syros Pharmaceuticals Inc Inhibitors of cyclin-dependent kinase 7 (cdk7)
KR102429220B1 (ko) * 2014-04-30 2022-08-04 더 트러스티이스 오브 콜롬비아 유니버시티 인 더 시티 오브 뉴욕 치환 4-페닐피페리딘, 그 제조 및 사용
GB201416754D0 (en) 2014-09-23 2014-11-05 Mission Therapeutics Ltd Novel compounds
NZ736450A (en) 2015-03-30 2022-04-29 Mission Therapeutics Ltd 1-cyano-pyrrolidine compounds as usp30 inhibitors
US10669234B2 (en) 2015-07-14 2020-06-02 Mission Therapeutics Limited Cyanopyrrolidines as dub inhibitors for the treatment of cancer
GB201521109D0 (en) 2015-11-30 2016-01-13 Mission Therapeutics Ltd Novel compounds
GB201522267D0 (en) 2015-12-17 2016-02-03 Mission Therapeutics Ltd Novel compounds
GB201522768D0 (en) 2015-12-23 2016-02-03 Mission Therapeutics Ltd Novel compounds
GB201602854D0 (en) 2016-02-18 2016-04-06 Mission Therapeutics Ltd Novel compounds
GB201603779D0 (en) 2016-03-04 2016-04-20 Mission Therapeutics Ltd Novel compounds
GB201604647D0 (en) 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
US11352339B2 (en) 2016-03-24 2022-06-07 Mission Therapeutics Limited 1-cyano-pyrrolidine derivatives as DUB inhibitors
JP6959332B2 (ja) 2016-09-27 2021-11-02 ミッション セラピューティクス リミティド Ｕｓｐ３０の阻害剤としての活性を有するシアノピロリジン誘導体
GB201616511D0 (en) 2016-09-29 2016-11-16 Mission Therapeutics Limited Novel compounds
GB201616627D0 (en) 2016-09-30 2016-11-16 Mission Therapeutics Limited Novel compounds
TWI771327B (zh) 2016-10-05 2022-07-21 英商使命醫療公司 新穎化合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Also Published As

Publication number Publication date
EP3430012A1 (fr) 2019-01-23
JP6959248B2 (ja) 2021-11-02
US11306096B2 (en) 2022-04-19
MA43745A (fr) 2018-11-28
US20210221813A1 (en) 2021-07-22
WO2017158381A1 (fr) 2017-09-21
GB201604638D0 (en) 2016-05-04
CN108473502B (zh) 2022-04-26
JP2019508462A (ja) 2019-03-28
WO2017158381A8 (fr) 2018-01-11
CN108473502A (zh) 2018-08-31

Similar Documents

Publication Publication Date Title
EP3430012B1 (fr) Dérivés de 4,6-dihydropyrrolo[3,4-c]pyrazole-5(1h)-carbonitrile pour le traitement du cancer
US11319287B2 (en) Cyanopyrrolidines as dub inhibitors for the treatment of cancer
US11958833B2 (en) Compounds
US11084821B2 (en) Cyanopyrrolidine derivatives with activity as inhibitors of USP30
US11390584B2 (en) 1-cyano-pyrrolidine compounds as USP30 inhibitors
TWI766882B (zh) 新穎化合物類
EP3523291B1 (fr) Hétérocycles cyano-substitués présentant une activité en tant qu'inhibiteurs de l'usp30

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20181016

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MISSION THERAPEUTICS LIMITED

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20200708

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602017040336

Country of ref document: DE

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1402268

Country of ref document: AT

Kind code of ref document: T

Effective date: 20210715

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210616

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210916

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210616

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210616

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1402268

Country of ref document: AT

Kind code of ref document: T

Effective date: 20210616

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20210616

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210616

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210917

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210916

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210616

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210616

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210616

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210616

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210616

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211018

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210616

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210616

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210616

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210616

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210616

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210616

VS25 Lapsed in a validation state [announced via postgrant information from nat. office to epo]

Ref country code: MD

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210616

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602017040336

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210616

26N No opposition filed

Effective date: 20220317

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210616

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210616

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210616

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20220331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220317

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220331

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220317

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220331

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20230327

Year of fee payment: 7

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230512

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20170317

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210616

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210616

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20240320

Year of fee payment: 8

Ref country code: GB

Payment date: 20240320

Year of fee payment: 8

VS25 Lapsed in a validation state [announced via postgrant information from nat. office to epo]

Ref country code: MA

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210616